Vonovia to complete the offer to the shareholders in Victoria Park and extends the acceptance period

On 3 May 2018, Vonovia SE, through its wholly-owned subsidiary Deutsche Annington Acquisition Holding GmbH (“Vonovia Acquisition Holding”), announced a recommended public cash offer to the shareholders of Victoria Park AB (publ) (“Victoria Park”) to tender all their shares in Victoria Park to Vonovia Acquisition Holding (the “Offer”) at a price of SEK 38.00 in cash for each Class A and Class B share and SEK 316.00 for each preference share (the “Offer Price”).[1] The acceptance period has expired and, according to the preliminary outcome of the Offer, shares in Victoria Park have been tendered to such an extent that Vonovia Acquisition Holding will become the owner of shares representing more than 58% of the total number of voting rights in Victoria Park on a fully diluted basis, including the shares for which call options were issued (see further below). All of the conditions for the completion of the Offer have thus been satisfied and Vonovia Acquisition Holding will complete the Offer. The final calculations of the shares tendered during the initial acceptance period is still in progress and the final outcome is expected to be announced on or around 21 June 2018. Settlement in respect of the Victoria Park shares duly tendered by 18 June 2018 is expected to occur on or around 28 June 2018. Vonovia Acquisition Holding has also decided to extend the acceptance period until 17.00 (CET) on 3 July 2018 to give remaining shareholders in Victoria Park the possibility to accept the Offer. Settlement in respect of shares tendered during the extended acceptance period is expected to occur on or around 3 July 2018 for the shareholders accepting the Offer no later than on 25 June 2018 and on or around 11 July 2018 for the shareholders accepting the Offer after 25 June 2018.[2] Based on the preliminary calculations, shares representing at least 46% of the voting rights in Victoria Park have been tendered during the initial acceptance period. In addition thereto, as previously communicated, shareholders have issued call options to Vonovia Acquisition Holding under which Vonovia Acquisition Holding has a right, but not an obligation, during the period 15-29 May 2019 to acquire 10,235,198 Class A shares and 14,264,946 Class B shares in Victoria Park (the “Call Option Shares”). The Call Option Shares represent approximately 10.04% of the total number of shares and 12.35% of the total number of voting rights in Victoria Park. The offer document in Swedish and English versions and other information about the Offer are published on http://se.vonovia-k.de/ (information in Swedish), http://en.vonovia-k.de/ (information in English) and on www.sebgroup.com/prospectuses. The information provided herein was submitted for publication on 18 June 2018, 9:40 p.m. CET. Information about the Offer Information about the Offer is made available at: http://en.vonovia-k.de/. For further information, please contact: Rene Hoffmann                                                                Klaus Markus Phone: +49 (0)234 314-1629                                             Phone: +49 (0)234 314-1149 E-mail: rene.hoffmann@vonovia.de                                  E-mail: klaus.markus@vonovia.de Brief description of Vonovia and Vonovia Acquisition Holding Vonovia is Germany’s leading nationwide residential real estate company. Vonovia currently owns and manages around 394,000 residential units in attractive cities and regions predominantly across Germany and manages around 58,000 units for third parties. Its Real Estate portfolio is worth approximately EUR 38.5 billion. As a modern service company, Vonovia focuses on customer orientation and tenant satisfac­tion. Offering tenants affordable, attractive and livable homes is a prerequisite for the company’s successful development. Accordingly Vonovia makes long-term investments in the maintenance, modernization and senior-friendly conversion of its properties. The company will also be creating more and more new apartments by realizing infill developments and adding to existing buildings. The company, which is based in Bochum, Germany, has been listed on the stock exchange since 2013 and was included in the DAX 30 in September 2015. Vonovia is also included in the international indices STOXX Europe 600, MSCI Germany, GPR 250 and EPRA/NAREIT Europe. Vonovia currently has a workforce of approximately 9,500 employees. Further information about Vonovia is available at www.vonovia.de. Vonovia Acquisition Holding is a wholly-owned subsidiary of Vonovia and is registered with the commercial register of the local court of Düsseldorf, Germany under registration no. HRB 56563. Vonovia Acquisition Holding is a holding company for various subsidiaries of the Vonovia group. Its business object is to acquire and hold assets and participations in other companies. Brief description of Victoria Park Victoria Park is a Swedish property company, which, through long-term management and social responsibility for more attractive living, creates value in an expanding property portfolio in growth districts in Sweden. As of 31 March 2018, Victoria Park’s property portfolio amounts to 1,083,000 square metres, comprising 13,725 flats, with a market value of SEK 16.2 billion. The shares in Victoria Park are listed for trading on Nasdaq Stockholm Mid Cap. Victoria Park is a limited liability company incorporated under the laws of Sweden, with corporate registration number 556695-0738. Important information The Offer, pursuant to the terms and conditions presented in the offer document, is not being made to persons whose participation in the Offer requires that any additional offer document is prepared or registration effected or that any other measures are taken in addition to those required under Swedish law. This press release and any related Offer documentation is not being published in or distributed to or into and must not be mailed or otherwise distributed or sent in or into any country in which the distribution or offering would require any such additional measures to be taken or would be in conflict with any law or regulation in such country. Persons who receive this press release (including, without limitation, nominees, trustees and custodians) and are subject to the law of any such jurisdiction will need to inform themselves about, and observe, any applicable restrictions or requirements. Any failure to do so may constitute a violation of the securities laws of any such jurisdiction. Vonovia Acquisition Holding, to the fullest extent permitted by applicable law, disclaims any responsibility or liability for the violations of any such restrictions by any person. Any purported acceptance of the Offer resulting directly or indirectly from a violation of these restrictions may be disregarded. The Offer is not being made, and will not be made, directly or indirectly, in or into, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa by use of mail or any other means or instrumentality of interstate or foreign commerce, or of any facilities of a national securities exchange, of Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. This includes, but is not limited to facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic transmission. The Offer cannot be accepted and shares may not be tendered in the Offer by any such use, means, instrumentality or facility of, or from within Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or by persons located or resident in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Accordingly, this press release and any documentation related to the Offer are not being and should not be mailed or otherwise transmitted, distributed, forwarded or sent in or into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or to any Australian, Canadian, Hong Kong, Japanese, New Zealand or South African persons or any persons located or resident or with a registered address in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Banks, brokers, dealers and other nominees holding shares for persons in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa must not forward this press release or any other documents received in connection with the Offer to such persons. Vonovia Acquisition Holding will not deliver any consideration from the Offer into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Any purported acceptance of the Offer resulting directly or indirectly from a violation of these restrictions will be invalid and any purported acceptance by a person located in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or any agent, fiduciary or other intermediate acting on a non-discretionary basis for a principal giving instructions from within Australia, Canada, Hong Kong, Japan, New Zealand or South Africa will be invalid and will not be accepted. Each holder of shares participating in the Offer will represent that it is not an Australian, Canadian, Hong Kong, Japanese, New Zealand or South African person, is not located in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa and is not participating in such Offer from Australia, Canada, Hong Kong, Japan, New Zealand or South Africa and that it is not acting on a non-discretionary basis for a principal that is an Australian, Canadian, Hong Kong, Japanese, New Zealand or South African person, that is located in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or that is giving an order to participate in such Offer from Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Notwithstanding the foregoing, Vonovia Acquisition Holding reserves the right to permit the Offer to be accepted by persons not resident in Sweden if, in its sole discretion, Vonovia Acquisition Holding is satisfied that such transaction can be undertaken in compliance with applicable laws and regulations. To the extent permissible under applicable law or regulation, Vonovia Acquisition Holding or its brokers may purchase, or conclude agreements to purchase, shares Victoria Park, directly or indirectly, outside of the scope of the Offer, before, during or after the period in which the Offer remains open for acceptance. This also applies to other securities which are directly convertible into, exchangeable for, or exercisable for Victoria Park shares, such as warrants. These purchases may be completed via the stock exchange at market prices or outside the stock exchange at negotiated conditions. Any information on such purchases will be disclosed as required by law or regulation in Sweden. This press release has been published in Swedish and English. Barclays Bank PLC, acting through its Investment Bank (“Barclays”), which is authorised by the Prudential Regulation Authority and regulated in the United Kingdom by the Financial Conduct Authority and the Prudential Regulation Authority, is acting exclusively for Vonovia and no one else in connection with the Offer and will not be responsible to anyone other than Vonovia for providing the protections afforded to clients of Barclays nor for providing advice in relation to the Offer or any other matter referred to in this announcement. J.P. Morgan Securities plc (“J.P. Morgan”), which is authorised by the Prudential Regulation Authority and regulated in the United Kingdom by the Financial Conduct Authority and the Prudential Regulation Authority, is acting exclusively for Vonovia and no one else in connection with the Offer and will not be responsible to anyone other than Vonovia for providing the protections afforded to clients of J.P. Morgan nor for providing advice in relation to the Offer or any other matter referred to in this announcement. Forward-looking information To the extent this press release contains forward-looking statements, such statements do not represent facts and are characterised by the words "will", "expect", "believe", "estimate", "intend", "aim", "assume" or similar expressions. Such statements express the intentions, opinions or current expectations and assumptions of Vonovia Acquisition Holding, for example with regard to the potential consequences of the Offer for Victoria Park, for those shareholders of Victoria Park who choose not to accept the Offer or for future financial results of Victoria Park. Such forward-looking statements are based on current plans, estimates and forecasts which Vonovia Acquisition Holding has made to the best of its knowledge, but which do not claim to be correct in the future. Forward-looking statements are subject to risks and uncertainties that are difficult to predict and usually cannot be influenced by Vonovia Acquisition Holding. It should be kept in mind that the actual events or consequences may differ materially from those contained in or expressed by such forward-looking statements. ---------------------------------------------------------------------- [1] If Victoria Park pays dividends or makes any other distributions to shareholders, for which the record date occurs prior to the settlement of the Offer, the Offer Price will be reduced accordingly. [2] See footnote 1. This applies, for example, to the dividend on the preference shares with record date on 29 June 2018.

Results on a par with last year, excluding non-recurring items

MQ Group profits for the third quarter, excluding non-recurring items, are on a par with last year despite a market that remains demanding and campaign-driven. Sales fell during the quarter, but this was compensated for in terms of profit by a higher gross margin and very good cost control. A transition programme was launched during the spring focusing on both income and efficiency so as to further speed up the work towards change.  Third quarter (March – May 2018)   ·  Net sales amounted to SEK 413 million (424), down 2.6 per cent. Like-for-like sales declined 4.3 per cent (according to the Swedish Retail Institute Index, the market’s comparable stores declined 1.4 per cent).  ·  The gross margin was 62.8 per cent (61.6).  ·  Operating profit was SEK 28 million (36), which corresponds to an operating margin of 6.7 per cent (8.4). Operating profit excluding non-recurring items was on a par with the previous year.   ·  Profit after tax for the period amounted to SEK 21 million (27), which equates to SEK 0.59 (0.77) per share after dilution.   ·  Cash flow from operating activities was SEK 27 million (4).  Nine-month period (September 2017 – May 2018)  ·  Net sales amounted to SEK 1,290 million (1,354), down 4.7 per cent. Like-for-like sales declined 6.0 per cent (according to HUI Research like-for-like sales for the market as a whole declined by 2.1 per cent).  ·  The gross margin was 58.3 per cent (58.2).  ·  Operating profit was SEK 59 million (91), which corresponds to an operating margin of 4.6 per cent (6.7).   ·  Profit after tax for the period amounted to SEK 44 million (69), which equates to SEK 1.26 (1.98) per share after dilution.   ·  Cash flow from operating activities was SEK 47 million (65).  For more information, please contact:Christina Ståhl, President and CEO: +46 (0)31-388 80 10Tony Siberg, Deputy CEO and CFO: +46 (0)31-388 84 01  This information is information that MQ Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 19 June 2018 at 07:15 CET.  

Ahlsell acquires Finnish distributor of HVAC brackets and installation tools

Ahlsell Oy has signed an agreement to acquire Kahipa Oy (Kahipa), a Finnish distributor of HVAC brackets and installation tools with annual sales of approximately MEUR 3,5. "Kahipa offers its customers specialist competence in a strategically important niche market. A bulk of the HVAC brackets are sold under private label, and we see good opportunities to extend the offering of these quality products nationwide.” says Mika Salokangas, Head of operations for Ahlsell in Finland. Kahipa has seven employees, two branches in the southern parts of Finland and cater to a broad customer base covering customers in all sizes, from small installation companies to big construction enterprises. “Both existing and new customers can look forward to an attractive and broad product assortment as we join forces.” continues Mika.The acquisition is expected to be closed in the beginning of July and have a minor positive impact on the Group's earnings in 2018. For further information please contact:Karin Larsson, Head of IR and external communications+46 8 685 59 24, karin.larsson@ahlsell.seJohan Nilsson, President and CEO, Ahlsell AB+468 685 70 00, johan.nilsson@ahlsell.se Ahlsell is the Nordic region’s leading distributor of installation products, tools and supplies for installers, construction companies, facility managers, industrial and power companies and the public sector. The unique customer offer covers more than one million individual products and solutions. The Group has a turnover of over SEK 28 billion and about 97 percent of revenue is generated in the three main markets of Sweden, Norway and Finland. With about 5,600 employees, more than 230 branches and three central warehouses, we constantly fulfil our customer promise: Ahlsell makes it easier to be professional! Press release, June 19, 2018

Addnode Group has conducted a directed share issue of 3 million class B shares

The Board of Directors of Addnode Group AB (publ) (“Addnode” or the “Company”) has, based on the issue authorisation granted by the annual general meeting on 26 April 2018, and as indicated in the Company’s press release on 18 June 2018, resolved on a directed share issue of 3 million new class B shares at a price of SEK 86 per share (the “Share Issue”), which means that the Company will receive gross proceeds of approximately SEK 258 million. The price per share in the Share Issue has been determined through an accelerated bookbuilding procedure. The Board of Directors of Addnode concludes that demand in the Share Issue was strong, as the communicated volume of approximately 3 million shares was oversubscribed by Swedish and international institutional investors shortly after the announcement of the Share Issue. The institutional investors taking part in the Share Issue include Creades, Cliens Kapitalförvaltning and Swedbank Robur. The reasons for the deviation from the shareholders' pre-emptive rights are to procure financing in a fast and effective way to enable acquisitions and continued growth, strengthen the institutional shareholder base and increase liquidity in the Company’s class B share. The total number of shares in the Company after registration of the Share Issue will amount to 33,427,256 (987,174 class A shares and 32,440,082 class B shares). The Share Issue entails a dilution of approximately 9.0 per cent, based on the total number of Addnode shares after the Share Issue. ABG Sundal Collier has acted as Sole Lead Manager and Bookrunner in the transaction. Cederquist acted as legal advisor to Addnode. This information is insider information that Addnode Group AB (publ) is required to publish in accordance with the EU market abuse regulation. The information was submitted for publication through the contact person stated below, at 8:00a.m. on 19 June 2018. Important informationThe release or distribution of this press release may, in certain jurisdictions, be subject to restrictions according to law and people in those jurisdictions, in which this press release has been announced or distributed, should inform themselves of and follow such legal restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Addnode in any jurisdiction. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed to the United States, Canada, Australia, South Africa, Japan, Hong Kong, Switzerland, Singapore, New Zealand or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations. This press release is not a prospectus. Addnode has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus has been prepared or will be prepared in connection with the directed new share issue.

Hexagon acquires SPRING Technologies, makers of machine tool simulation and verification software

Hexagon AB, a global leader in digital solutions, today announced the acquisition of SPRING Technologies, a software provider specialising in integrated solutions for optimising the machining workflow through machine tool simulation, toolpath verification and optimisation, and machine tool management. Its solutions are in use at major OEMs and suppliers worldwide, helping streamline the manufacturing process through the optimisation of machine tool performance and productivity.SPRING Technologies has been pioneering innovative Computer Numerical Control (CNC) solutions for machine tools for over 30 years. Its flagship portfolio, NCSIMUL, is a comprehensive suite of integrated solutions providing native CNC code programming, CNC simulation, cutting and tool libraries, CNC program management, real-time machine monitoring and technical content publication. Together, they enable complete mastery of the machining process across a variety of manufacturing sectors including aerospace, automotive, medical, energy, and transportation.“Manufacturing must be ‘smart’ if it’s to produce the next generation of products at reduced costs. The acquisition of SPRING Technologies further strengthens our Autonomous Connected Ecosystem (ACE) strategy which will ultimately enable the smart factory,” said Ola Rollén . “Machining simulation is essential to connecting the physical world with the digital and achieving autonomy – both of which are prerequisites to delivering smart factory solutions.”Headquartered in France, with offices in America, Germany and China, SPRING Technologies employs around 100 people. The company will operate within Hexagon’s Manufacturing Intelligence division as part of the CAD/CAM and production software business currently led by the Vero Software brand.SPRING Technologies will be fully consolidated as soon as regulatory approval has been obtained. The acquisition has no significant impact on Hexagon’s earnings.For further information, please contact:Maria Luthström, Investor Relations Manager, Hexagon AB, +46 8 601 26 27, ir@hexagon.com Kristin Christensen , Chief Marketing Officer, Hexagon AB, +1 404 554 0972, media@hexagon.com 

Rejlers signs comprehensive agreement with major telecom operator

“Under the new agreement, we will carry out network planning and order 25 percent of the telecom operator’s B2B fibre deliveries, an assignment we are very proud to carry out,” said Christina Stöllman Nilsson and Anne-Louise Norman, Group Managers at Rejlers Sweden. Greater flexibility presents new opportunitiesRejlers’ functional solution affords customers a flexible and cost-effective solution and frees up time which can be spent on development projects, for example. The partnership also opens up more opportunities to handle volume changes easily and leads to improved delivery precision across the country. “The new agreement reflects the success of our previous partnership, which is now set to be deepened further,” said Christina Stöllman Nilsson and Anne-Louise Norman. For further information:Magnus Albinsson, Head of Division Rejlers Sweden, +46 (0)76 669 71 23, e-mail: magnus.albinsson@rejlers.seLisa Rejler; acting Communication Director, tel. +46 (0)70 399 08 06, e-mail: lisa.rejler@rejlers.seRejlers is one of the largest engineering consultancy firms in the Nordic region. Our 2,000 experts work with projects in the areas of Energy, Buildings, Industry, Infrastructure and Telecom. At Rejlers, you will meet specialist engineers with the knowledge, cutting edge expertise and energy to achieve results. We can be found in 75 locations in Sweden, Finland and Norway. Rejlers recorded revenue of SEK 2.5 billion in 2017 and its class B share is listed on Nasdaq Stockholm.

Ongoing MTG split process to follow completion of Kinnevik share distribution

MTG and NENT Group will operate as separate companies from 1 July 2018 as previously announced, and the Board of Directors of NENT Group held its first constituent Board meeting in London last Friday. The members of the Board of NENT Group comprise current MTG Board Directors David Chance (Chairman), Simon Duffy and Nathalie Tydeman. Additional Board members will be appointed in due course. Separately, MTG and TDC A/S (“TDC Group”) have terminated the previously announced merger agreement to combine MTG Nordics (MTG Nordic Entertainment and MTG Studios) and TDC Group. The termination follows the completion of the previously announced public takeover offer for all of TDC Group’s shares by a financial consortium. **** NOTES TO EDITORS MTG (Modern Times Group MTG AB (publ)) is a leading international digital entertainment group and we are shaping the future of entertainment by connecting consumers with the content that they love in as many ways as possible. Our brands span TV, radio and next generation entertainment experiences in esports, digital video content and online gaming. Born in Sweden, our shares are listed on Nasdaq Stockholm (‘MTGA’ and ‘MTGB’). This information is information that MTG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, at 08:00 CET on 19 June 2018. Contact us:press@mtg.com (or Tobias Gyhlénius, Head of Public Relations; +46 73 699 27 09)investors@mtg.com (or Stefan Lycke, Head of Investor Relations; +46 73 699 27 14)Download high-resolution photos: Flickr Follow us:mtg.com  / Facebook  / Twitter  / LinkedIn  / Instagram  / YouTube To read MTG’s Privacy Policy : click here 

Portuguese hospital expands its VNA from Sectra with digital pathology to improve cancer care

“Sectra’s digital pathology solution gives us access to already-proven calculation algorithms that will translate into greater reproducibility of results and have an impact on clinical decisions,” says Dr. José Cabeçadas, Pathology Manager, Instituto Português de Oncologia de Lisboa. IPO Lisboa is expanding its medical imaging IT solution for radiology to also include pathology. The solution will provide pathologists with instant access to images and related data, digital tools for reviewing the images and the ability to collaborate across both departments and locations. “The use of a single system for the entire hospital guarantees a universal availability of resources and the possibility to work remotely,” continues Dr. Cabeçadas. “An immediate additional benefit is that the solution will provide increased efficiency in the preparations for multidisciplinary meetings.” Sectra’s digital pathology solutionSectra’s digital pathology solution includes digital tools which enable the pathologists to make their diagnoses and carry out reporting with higher precision and less time spent per case. It is a complete, vendor-neutral solution for primary diagnostics that includes storage solutions and an advanced review workstation. Sectra’s pathology solution is part of Sectra’s Enterprise Image Management (EIM) solution. Sectra’s enterprise imaging portfolio provides a unified strategy for all imaging needs, and improves patient outcomes while lowering operational costs. The scalable and modular solution supports the most image-intense departments—radiology, breast imaging, pathology, cardiology and orthopaedics. Being built on the same technical platform, customers can easily extend a departmental solution to create a comprehensive VNA. Read more about Sectra Enterprise Image Management and why Sectra PACS is “Best in KLAS” at https://www.sectra.com/medical/.

Breakthrough recognition for Veoneer’s LIV research platform

On June 13, CLEPA, the European Association of Automotive Suppliers, organized for the third time in a row the CLEPA Innovation Awards Gala, in The Hague, Netherlands. The gala was a breakthrough for Veoneer’s LIV research platform. LIV demonstrates how we can achieve greater safety benefits from automation, as the car and driver will work together to achieve the driver’s goals in a smooth and fast way. LIV is an artificial intelligence-equipped car with the capability to understand and respond to context. When driving with LIV, drivers will not shut systems off which often is the case in ordinary cars, but keep using them, thus increasing the safety benefits of all safety systems available. LIV finished as second in two separate categories, Safety and Connectivity & Automation, the only project to receive award in more than one category. “This was a recognition that trust and human/system interaction will be a key to success in automation and autonomous driving,” says Jan Carlson, Chairman, President and CEO of Veoneer after the spin-off from Autoliv has been completed. Inquiries: Thomas Jönsson, Group Vice President Communications, Tel +46 (0)8 58 72 06 27 About Veoneer Veoneer has the ambition to be a leading system supplier for advanced driver assistance systems (ADAS) and autonomous driving as well as a market leader in automotive safety electronics products. Veoneer designs and builds state-of-the-art hardware, software, and electronic systems and its offering includes active safety products such as automotive radars, cameras with driver assist systems, night vision systems and positioning systems, restraint control systems, and brake systems. Veoneer and its joint-ventures has 7,500 employees in 13 countries. Veoneer is currently a subsidiary of Autoliv, Inc. with its stock-listing expected on July 2, 2018 on the New York Stock Exchange under the symbol “VNE” and on Nasdaq Stockholm under the symbol “VNE SDB”. About Autoliv Autoliv, Inc. is the worldwide leader in automotive safety systems, and through its subsidiaries develops and manufactures automotive safety systems for all major automotive manufacturers in the world. Together with its joint ventures, Autoliv has more than 72,000 employees in 27 countries. In addition, the Company has 23 technical centers in nine countries around the world, with 19 test tracks, more than any other automotive safety supplier. Sales in 2017 amounted to about US $10.4 billion. The Company's shares are listed on the New York Stock Exchange (NYSE: ALV) and its Swedish Depository Receipts on Nasdaq Stockholm (ALIV sdb). For more information about Autoliv, please visit our company website at www.autoliv.com. “Safe Harbor Statement” This release contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future, including those related to the completion and timing of the spin-off and distribution, including the satisfaction of the conditions to the distribution and the receipt of all required regulatory approvals, and the expected performance of Autoliv and Veoneer following completion of the spin-off. All forward-looking statements are based upon our current expectations, various assumptions and/or data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements, including general economic conditions and fluctuations in the global automotive market. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any forward-looking statements in light of new information or future events, except as required by law. 

Alfa Laval wins SEK 60 million offshore order

The order comprises offshore pumping systems, which will supply water to the onboard fire extinguishing system. “I am very pleased to announce this large order for our Framo pumping systems. Their proven capacity and reliability makes them highly suitable for the tough conditions offshore,” says Peter Leifland, President of the Marine Division. Did you know that… Framo, an Alfa Laval brand, has unique pumping solutions for different duties; cargo, oil and gas production and offshore supply?  About Alfa Laval                                                                                                         Alfa Laval is a leading global provider of specialized products and engineering solutions based on its key technologies of heat transfer, separation and fluid handling. The company’s equipment, systems and services are dedicated to assisting customers in optimizing the performance of their processes. The solutions help them to heat, cool, separate and transport products in industries that produce food and beverages, chemicals and petrochemicals, pharmaceuticals, starch, sugar and ethanol. Alfa Laval’s products are also used in power plants, aboard ships, oil and gas exploration, in the mechanical engineering industry, in the mining industry and for wastewater treatment, as well as for comfort climate and refrigeration applications. Alfa Laval’s worldwide organization works closely with customers in nearly 100 countries to help them stay ahead in the global arena. Alfa Laval is listed on Nasdaq OMX, and, in 2017, posted annual sales of about SEK 35.3 billion (approx. 3.6 billion Euros). The company has about 16 400 employees. www.alfalaval.com  For more information please contact:Peter TorstenssonSenior Vice President, CommunicationsAlfa LavalTel: + 46 46 36 72 31Mobile: +46 709 33 72 31Gabriella GrotteInvestor Relations ManagerAlfa LavalTel: +46 46 36 74 82Mobile: +46 709 78 74 82

Change in Volvo’s Group Executive Board

The current Deputy CEO and CFO Jan Gurander will continue his work as Deputy CEO with the task of leading Volvo’s strategic and operational activities together with President and CEO Martin Lundstedt. In a world that is changing at an increasingly rapid rate, Jan Gurander will assume responsibility for a number of the Group’s key challenges and strategic issues. Jan Ytterberg, born in 1961, has been appointed CFO and will become a new member of the Volvo Group Executive Board. Jan Ytterberg currently serves as the CFO of Swedish company Husqvarna Group and has almost thirty years’ of previous experience from the automotive industry from his various positions at truck manufacturer Scania. The date on which Jan Ytterberg will take up his new position is yet to be decided. In addition, the current Executive Vice President Group Human Resources Kerstin Renard will step down from her role at the end of the year. The process of recruiting her successor has been initiated. “I have great respect for Kerstin Renard’s work over her 11 years at Volvo,” said Martin Lundstedt. “She has led the Group’s HR activities and delivered excellent results in both times of prosperity and a difficult financial crisis.” June 19, 2018 Journalists who would like further information, please contact: Joakim Kenndal, Head of Media relations, Volvo Group, tel, 46 31 323 72 29.  For more information, please visit volvogroup.com/pressThe Volvo Group is one of the world’s leading manufacturers of trucks, buses, construction equipment and marine and industrial engines. The Volvo Group also provides complete solutions for financing and service. Volvo, which employs almost 100,000 people, has production facilities in 18 countries and sells its products in more than 190 markets. In 2017, the Volvo Group’s sales amounted to about SEK 335 billion (EUR 33.4 billion) and its shares are listed on Nasdaq Stockholm.  

Itiviti partners with Syspower of Taiwan to expand NYFIX global connectivity footprint in Asia

Syspower already benefits from a prevalent position in Taiwan. Over the past decade, the firm has built a strong local market presence allowing buy-side and sell-side financial institutions to reach over 500 connections through its FIXNet connectivity network. Syspower decided to turn to Itiviti’s NYFIX to address the growing demand from Taiwanese institutions to connect to international trading venues. Itiviti has a strong growth strategy for the NYFIX Marketplace international trading network, leveraging the platform’s ability to seamlessly connect with any OMS solutions. This “plug and connect” feature naturally positions NYFIX as the go-to solution for local vendors looking to expand their international footprint at minimal cost. The Itiviti-Syspower partnership is already proving fruitful for the two companies with new clients signed following the availability of the joint offering and prospective business opportunities lining up. “Working with experienced international vendors is second nature for Taiwan firms as we operate in an increasingly globalized marketplace,“ said Stony Fan, Chairman of Syspower. “The quality of our exchanges with Itiviti from our first meetings and the support our teams received during the whole process were fantastic; getting customers live was a simple, fully managed process. This partnership gives us confidence that we can expand greatly.” Philippe Carré, Itiviti Global Head of Business Development commented: “We see a great fit between our expansion strategy in Asia and the growing demand from local technology vendors to extend their reach. Launched early 2017, our NYFIX hub in Asia has helped sustain intense market demand and, under the Itiviti GAP - Global Alliance Program, to onboard a number of key regional partners. making NYFIX the Asian FIX connectivity utility of choice.” Ofir Geffen, President Director Asia Pacific and Japan, Itiviti, adds: “We harbor ambitious plans for our Asian development, with half of the Itiviti offices already located in the region - I firmly intend to make it one of our strongest business. It is essential for us to leverage a strong pan-Asian ecosystem of providers to sustain the growth dynamic – I am delighted to welcome Syspower as our latest partner.” For further information, please contact:Christine Blinke, Chief Marketing Officer, Itiviti, Tel. +46 739 01 02 01, christine.blinke@itiviti.com  About SyspowerSyspower is a leading IT service provider with solid industry knowhow, especially in financial category. With fruitful experience in financial industry operations and skillful talents, Syspower has won high reputation and recognition from customers over the years. FIXNet is the leading trading platform operated by Syspower. It provides financial transaction services, including securities and options, which was ranked in the first place in Taiwan’s financial trading market. For more information about Syspower, please visit www.syspower.com.tw or write to customer@syspower.com.tw. About ItivitiItiviti is a market-leading global provider of multi-asset trading technology and financial infrastructure solutions for buy-side and sell-side market participants, including NYFIX, one of the industry’s largest FIX-based trading communities. Serving around 2000 clients worldwide, we provide consistent, reliable access to the most up-to-date and innovative order routing, connectivity and trading solutions available. Top-tier trading firms, banks, brokers, exchanges and institutional investors rely on our technology, solutions and expertise to streamline their daily operations, connect to their desired markets, and trade when and where they want. All while being able to comply with global regulation. With global offices in 18 locations covering all major financial centers the merger of Itiviti and ULLINK in March 2018 created a full-service technology and infrastructure provider, covering all asset classes, geographies and regulatory landscapes. For more information, please visit www.itiviti.com or www.ullink.com. Itiviti is owned by Nordic Capital Fund VII. 

OptiGroup to acquire Moonen Packaging in the Netherlands

OptiGroup has agreed to acquire 100 percent of the shares of the Dutch packaging distributor Packagegroup Moonen B.V. The transaction, which is subject to approval by the Dutch Competition Authority, is expected to be completed during the summer. The purchase price has not been disclosed. Moonen Packaging, with revenues of EUR 51 million in 2017 and around 80 employees, has been a family business since the 1950s and is a leading and fast growing distributor of packaging solutions in the Benelux. The company designs, develops, sources, stocks, sells and distributes customised packaging solutions as well as hygiene paper, cleaning and catering products. Moonen Packaging is a European leader in the field of sustainability with focus on cost-effective and environmentally friendly packaging solutions for the industrial and retail sector. The comapny has won the prestigious “most sustainable company in the Netherlands” award. The acquisition of Moonen Packaging follows the recent acquisitions of three other packaging distributors by OptiGroup: Telpak and Mercamer in Finland, and Proxima in Romania. Moonen Packaging will continue to be led by Gé Moonen, who has successfully grown and developed the Company for the last 12 years. OptiGroup’s President and CEO, Christoph Sander comments:“We have followed Moonen Packaging for a long time as a European leader in sustainable packaging, with a strong market position in the Benelux and a long history of developing innovative products and services. Subject to clearance by the Dutch competition authority, we look forward to working together closely. We will provide further information at the appropriate time.” Gé Moonen, Managing Director and third generation owner of Moonen Packaging comments:“Moonen Packaging has been our family business for many years and it has been very important for me to find the right long-term home for the company and all our employees. Potentially becoming part of OptiGroup means that we can develop the business even faster and with access to OptiGroup’s wider assortment. I am certain this combination will benefit existing and new customers and suppliers. OptiGroup shares my passion for sustainable packaging, which is also very important.”

EQT granted exclusivity to acquire Azelis, a global distributor of specialty chemicals and food ingredients

· EQT VIII, with PSP Investments as co-investor, is in exclusive discussions to acquire Azelis, a leading distributor of specialty chemicals and food ingredients with a global presence in more than 40 countries · Azelis provides a diverse range of products and innovative services to more than 43,000 customers and 2,000 principals · EQT VIII to support Azelis’ continued growth by leveraging EQT’s experience with buy-and-build strategies, digital capabilities and global network of industrial advisors The EQT VIII fund (“EQT” or “EQT VIII”), in partnership with the Public Sector Pension Investment Board (“PSP Investments”) as co-investor, has been granted exclusivity to finalize the discussions to acquire Azelis (“Azelis” or “the company”) from funds advised by Apax Partners. Azelis was established in 2001 through the merger of Novorchem (Italy) and Arnaud (France). It has since followed an active acquisition strategy to create a leading specialty chemical distribution network in Europe. Today, Azelis supports more than 43,000 customers who benefit from its applicationknow-how and technical support and have access to a wide product portfolio from more than 2,000 specialty raw materials producers. The company has 1,800 employees and sales of around EUR 1.8 billion. EQT will support Azelis’ continued development by providing access to both operational and financial resources and by leveraging EQT’s expertise with buy-and-build strategies. In addition, EQT will provide digital capabilities and grant the company access to a global network of industrial advisors. Azelis’ current management team, under the leadership of Dr. Hans-Joachim Müller, will continue to lead the organization. “Azelis holds a leading position in the attractive specialty chemical distribution space,” said Bert Janssens, Partner at EQT Partners, Investment Advisor to EQT VIII. “We have been impressed by how Azelis’ management team transformed the business from a predominantly European operator to a leading global platform. EQT looks forward to working with Hans-Joachim and his team on their continued growth journey.” “We are constantly strengthening our capabilities to serve our key suppliers (“principals”) and our diverse base of customers,” said Dr. Hans-Joachim Müller, CEO of Azelis. “We are grateful for Apax’s support over the past three years and are excited to continue our journey together with EQT.” EQT draws on comprehensive expertise and competence in business services. Since 1994, EQT has invested in many companies within the services sector. “EQT applies a long-term, responsible and sustainable development approach, relying on a consistent industrial logic,” explained Kristiaan Nieuwenburg, Partner at EQT Partners, Investment Advisor to EQT VIII. “Azelis will benefit from this growth-focused investment philosophy, as well as our sector expertise.” “Strong relationships with leading private equity firms are at the core of our investment strategy, and we are excited to partner with EQT for the acquisition of Azelis,” said Simon Marc, ‎Managing Director and Head of Private Equity at PSP Investments. “Azelis is a global leader in an attractive market that has strong consolidation prospects. We are very pleased to back Azelis and its world-class management team in their next stage of growth.” The transaction is subject to regulatory approvals and the necessary consultation with employee representatives being conducted, and is expected to close in the fourth quarter of 2018. The parties have agreed not to disclose the transaction value. ContactsBert Janssens, Partner at EQT Partners, Investment Advisor to EQT VIII, +31 202 62 4001EQT Press office, +46 8 506 55 334Verena Garofalo, Advisor, External Communications and Media Relations, PSP Investments, +1 514 218-3795, media@investpsp.ca About EQTEQT is a leading investment firm with approximately EUR 50 billion in raised capital across 27 funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. More information: www.eqtpartners.com About AzelisAzelis is a leading distributor of specialty chemicals and food ingredients present in over 40 countries across the globe with around 1,800 employees. Our knowledgeable teams of industry, market and technical experts are each dedicated to a specific market within Life Sciences and Industrial Chemicals. We offer a lateral value chain of complementary products to over 40,000 customers, creating a turnover of EUR 1.8 billion. In the US we operate under a number of renowned co-brands that cater to the various markets in the region. More information: www.azelis.com About PSP InvestmentsThe Public Sector Pension Investment Board (PSP Investments) is one of Canada's largest pension investment managers with USD 153 billion of net assets as of March 31, 2018. It manages a diversified global portfolio composed of investments in public financial markets, private equity, real estate, infrastructure, natural resources and private debt. Established in 1999, PSP Investments manages net contributions to the pension funds of the federal Public Service, the Canadian Forces, the Royal Canadian Mounted Police and the Reserve Force. Headquartered in Ottawa, PSP Investments has its principal business office in Montréal and offices in New York and London. For more information, visit www.investpsp.com or follow us on Twitter and LinkedIn.

Targovax granted EU Patent for mutant-RAS neoantigen platform 2nd generation product TG02

Oslo, 19 June 2018: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), is a clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors, announces that the European Patent Office has granted European Patent no 3079715, A Peptide mixture. The patent protects the composition of Targovax's mutant-RAS specific neoantigen vaccine TG02, for stimulating the immune system of cancer patients with RAS mutated tumors. Targovax’s proprietary mutant-RAS neoantigen vaccine platform is designed to treat patients with tumors harboring RAS mutations. Mutations in the RAS genes are a driving cause of cancer development and progression, and is linked to poor prognosis. By inducing an anti-mutant-RAS specific immune response, the TG products have the potential to delay disease progression and increase survival, with a favorable safety profile compared to chemotherapy and many other treatment options. TG02 expands the coverage of RAS mutations beyond TG01, and is targeting all relevant RAS exon 2 oncogenic point mutations which are found in the vast majority of all RAS mutated cancers. Currently, TG02 is being tested in an exploratory Phase Ib clinical trial in patients with locally recurrent RAS-mutated colorectal cancer in combination with the checkpoint inhibitor KEYTRUDA® (clinical study CT TG02-01). This study will provide important clinical data on the safety, immune activation and mechanism of action of TG02. Jon Amund Eriksen, inventor of the TG technology and Co-founder of Targovax, said: "We are glad to see the European patent for TG02 being granted, further strengthening Targovax's intellectual property portfolio covering the very important mutant-RAS trunk neoantigens. RAS is mutated in 20-30% of all cancers, and this 2nd generation product from the TG platform puts Targovax in a position to address an important unmet medical need, which could eventually benefit all RAS mutated cancer patients." For further information, please contact:Renate Birkeli, Investor RelationsPhone: +47 922 61 624Email: renate.birkeli@targovax.com  Media and IR enquires:Andreas Tinglum - Corporate Communications (Norway)Phone: +47 9300 1773Email: andreas.tinglum@corpcom.noSimon Conway/Stephanie Cuthbert - FTI Consulting (International)Phone: +44 20 3727 1000Email: Targovax@fticonsulting.com About Targovax  Activating the patient's immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine. Targovax’s primary product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, used as potential multi-target, neo-antigen therapeutic cancer vaccines. It has been engineered as an immune activator that selectively targets cancer cells. In phase I trials it has demonstrated immune activation at lesional level which was associated with clinical benefit. ONCOS-102’s lead indication is mesothelioma where the virus is currently being developed in a phase II trial. A second trial, in advanced melanoma, is expected to produce important proof of concept data for checkpoint inhibitor refractory patients. In addition, Targovax has a neo-antigen cancer vaccine under development targeting tumors that express mutated forms of RAS. Key proof of concept data for the TG platform from a clinical trial of TG01 in resected pancreatic cancer patients showed encouraging overall survival. A next generation product candidate, TG02 is currently being combined with pembrolizumab in a phase I trial in colorectal cancer. Both platforms are protected by an extensive portfolio of IP, know-how, and have the potential to yield multiple product candidates.

The Volvo FH 25 Year Special Edition — a tribute to an icon

To celebrate the introduction of the Volvo FH in 1993, a quarter of a century ago, Volvo Trucks releases The Volvo FH 25 Year Special Edition. Available as both Volvo FH and Volvo FH 16, it is characterized by its distinctive exterior and interior design, superb driver comfort and state-of-the-art features. Volvo FH is one of the industry's most successful models ever with nearly 1 million trucks sold, creating a way of life for millions of drivers all over the world. The Volvo FH 25 Year Special Edition is therefore not only a celebration of the truck itself but also a tribute to all the customers and drivers who have been driving this icon for the past 25 years. “Volvo FH is the perfect representation of a customer focused mindset and a model that has been pushing the boundaries for a quarter of a century. This magnificent edition truck is therefore both a tribute to the first 25 years and a starting point for our continued successful journey with customers and drivers”, says Claes Nilsson, President Volvo Trucks. “The first-generation Volvo FH meant so much for Volvo Trucks and the whole industry. It was a milestone; in fact, it was a game changer that totally transformed the perception of a modern truck. Working on the design of the edition truck has been a real honor,” says Nigel Atterbury, Senior Graphic Designer at Volvo Trucks. The exterior of this special edition is best described as contemporary with a retro twist. The silver/grey and orange décor highlights the truck’s origin and the striping forms the number 25 to signal the anniversary. The striping combines 3D effects and shadows to echo the design trend of the early 1990’s and gives the truck a distinct retro look. There are two launch colors, one darker, cool grey tone (Mammoth Tree Metallic) and a shiny red (Crimson Pearl), the latter a modern tribute to the original red cab color of 1993. When opening the door, a premium and luxurious interior awaits the driver. Safety has always been key in the Volvo FH and this passion is manifested by orange details in everything from seat belt stitches to curtains, carpets and reflective safety door decals. Using subtle, yet distinct accents, the design team has created a continuation of the safety and driver focus that has always been essential in the Volvo FH. And to enhance a great driving experience, the seats combine quilt and leather to offer exceptional comfort and design. The edition truck also embodies how the Volvo FH has been and remains an innovation leader. It includes some of the truck’s latest breakthroughs and it can be specified with the brand-new extensions to Volvo Dynamic Steering: · Volvo Dynamic Steering with Stability Assist. Designed to prevent skidding accidents. · Volvo Dynamic Steering with Lane Keeping Assist. Engineered to help the driver stay in lane, preventing collisions and roll-over accidents. · Volvo Dynamic Steering with Personal Settings. Allows individual adjustment of steering wheel resistance for convenient and comfortable driving. “This truck really shows how Volvo Trucks is driving progress and continues to set new standards in trucking, just like the Volvo FH has done since 1993,” says Tomas Thuresson, Global Long Haul Segment Manager at Volvo Trucks, and concludes: “It is a fantastic edition that pays tribute to a quite outstanding truck and the millions of people; customers, drivers and fans that have been engaged in the Volvo FH for 25 years.” Facts: Volvo FH 25 Year Special EditionVolvo FH and FH16, Globetrotter high sleeper cab or Globetrotter extra high sleeper cab.Two launch colours: Crimson Pearl or Mammoth Tree Metallic. Volvo FH 25 Year Special Edition branded interior and exterior:- Globetrotter sign- Striping- Emblems- customized interior design (curtains, carpets, seats, safety door decals etc.). The Volvo FH 25 Year Special Edition will be built for a limited period during 2018 and 2019. Sales will begin in end of June 2018 (week 25).  Direct link to images in high resolution Link to web site about FH 25 years  June 19, 2018 For further information, please contact:Fredrik Klevenfeldt, Director Public Relations and Social Media, Volvo TrucksTel: +46 31 3221106; email: fredrik.klevenfeldt@volvo.com  Press images and films are available in the Volvo Trucks image and film gallery at http://images.volvotrucks.com   Volvo Trucks provides complete transport solutions for professional and demanding customers, offering a full range of medium to heavy duty trucks. Customer support is secured via a global network of 2,100 dealers and workshops in more than 130 countries. Volvo trucks are assembled in 16 countries across the globe. In 2017, more than 112,000 Volvo trucks were delivered worldwide. Volvo Trucks is part of Volvo Group, one of the world’s leading manufacturers of trucks, buses, construction equipment and marine and industrial engines. The Group also provides complete solutions for financing and service. Volvo Trucks´ work is based on the core values of quality, safety and environmental care.

Mechanism controlling multiple sclerosis risk identified

Multiple sclerosis is a chronic inflammatory disease of the central nervous system, affecting people at a relatively young age. Most are between 20 and 40 years old when they get the first symptoms, in the form of, for example numbness in the arms and legs, visual impairment and dizziness, but also fatigue and depression. The symptoms are caused by an inflammation in the brain and the spinal cord that breaks down the myelin sheath protecting the nerves, thus damaging the axons. Currently there is no cure for MS, but the disease activity can often be halted through medication. Already over 40 years ago it was discovered that genetic variation in the so-called HLA region is the strongest risk factor for developing disease. HLA encodes molecules that are involved in the immune system. However, the specific genes and molecular mechanisms behind the emergence of the disease are not fully established. By using molecular analyses and combining several studies (so-called meta-analysis), including around 14,000 patients with MS and a control group of more than 170,000 healthy individuals, researchers at Karolinska Institutet found that people with the major risk variant HLA-DRB1*15:01 have an increased expression of the HLA-DRB1 gene, thus increasing the risk for the disease. The researchers further discovered a so-called epigenetic regulation of HLA expression as the mechanism mediating this effect. “We show for the first time that epigenetic mechanisms can cause the disease. In addition, we can connect this mechanism to the genetic variant with the strongest risk for developing MS,” says Maja Jagodic, researcher at the Department of Clinical Neuroscience at Karolinska Institutet and one of the authors of the article. The researchers also discovered a new HLA gene variant, rs9267649, which reduces the risk of developing MS. This protective variant decreases the HLA-DRB1 gene expression – through the same epigenetic regulation mechanism – thus reducing the risk for MS. The results open new avenues for potential alternative treatments based on specific epigenetic modulation, i.e. to prevent gene expression artificially. This gives hope for people with MS, as well as other autoimmune diseases. “Almost all autoimmune diseases are associated with HLA,” says Lara Kular, co-author and researcher at the same department. The study was carried out through an international collaboration with researchers in the US, Germany, Norway, Denmark, and Iceland (the deCode company). Financing has been granted through funding from, among others, the Swedish Research Council, Neuro, the Swedish Brain Foundation, the European MS Foundation, Petrus and Augusta Hedlund Foundation, AFA Insurance, Knut and Alice Wallenberg Foundation, Stockholm County Council, and AstraZeneca. Several of the researchers are employed by deCode genetics/Amgen Inc. For more information, see the scientific article. Publication: ”DNA methylation as a mediator of HLA-DRB1*15:01 and a protective  variant in multiple sclerosis ” . Lara Kular, Yun Liu, Sabrina Ruhrmann, Galina Zheleznyakova, Francesco Marabita, David Gomez-Cabrero, Tojo James, Ewoud Ewing, Magdalena Lindén, Bartosz Górnikiewicz, Shahin Aeinehband, Pernilla Stridh, Jenny Link, Till F. M. Andlauer, Christiane Gasperi, Heinz Wiendl, Frauke Zipp, Ralf Gold, Björn Tackenberg, Frank Weber, Bernhard Hemmer, Konstantin Strauch, Stefanie Heilmann-Heimbach, Rajesh Rawal, Ulf Schminke, Carsten O. Schmidt, Tim Kacprowski, Andre Franke, Matthias Laudes, Alexander T. Dilthey, Elisabeth G. Celius, Helle B. Søndergaard, Jesper Tegnér, Hanne F. Harbo, Annette B. Oturai, Sigurgeir Olafsson, Hannes P. Eggertsson, Bjarni V. Halldorsson, Haukur Hjaltason, Elias Olafsson, Ingileif Jonsdottir, Kari Stefansson, Tomas Olsson, Fredrik Piehl, Tomas J. Ekström, Ingrid Kockum, Andrew P. Feinberg, and Maja Jagodic. Nature Communications, online 19 June 2018, doi: 10.1038/s41467-018-04732-5.

Kesko further strengthens its Byggmakker chain in Norway – acquires Gipling AS

Kesko Corporation's subsidiary Byggmakker Handel AS has agreed to purchase Gipling AS, a Norwegian operator in the building and home improvement trade with net sales of approximately €151 million in 2017. With the acquisition of Skattum Handel AS, announced on 7 June, the Byggmakker chain will now have control over 30 Byggmakker stores, providing even greater potential for growth and increased profitability in Norway.  K Group’s building and technical trade division operates in eight countries. Byggmakker is one of the leading operators in the building and home improvement trade in Norway. Byggmakker Handel AS is now strengthening its operations by acquiring the largest Byggmakker retailer Gipling AS. The acquisition follows the recent acquisition of the second largest Byggmakker retailer Skattum Handel AS, announced on 7 June. Gipling AS operates 19 Byggmakker stores and employs some 540 professionals around the Trondheim area. In 2017, the company made €5.5 million in operating profit. “We have now acquired the two largest Byggmakker retailers to secure significant volume for the Byggmakker chain in Norway. The acquisitions of both Skattum Handel and now Gipling strengthen our possibilities for further growth and profitability in Northern Europe. The transaction price of the acquired companies, including financial liabilities, is some €147 million. In 2017, the companies’ combined net sales totalled €245 million and EBITDA €11.5 million,” says Jorma Rauhala, President of Kesko’s building and technical trade division and deputy to Kesko's President and CEO. In the building and technical trade, Kesko’s strategic objective is to strengthen its market position in Northern Europe and improve profitability in all operating countries. In Norway, the division operates 25 Onninen stores and 65 Byggmakker stores, of which 35 will operate under the retailer business model and 30 will be operated by the Byggmakker chain following the transaction. Gipling AS, headquartered in Steinkjer, operates Byggmakker stores in the counties of Nordland, Nord-Trøndelag, Sør-Trøndelag and Hedmark. The completion of the acquisition is subject to the approval of the Norwegian competition authorities and the fulfilment of the other terms and conditions of the transaction. Further information:Jorma Rauhala, Deputy to President and CEO of Kesko Corporation, President of the building and technical trade division, tel. +358 105 322 211, jorma.rauhala@kesko.fiJessica Diktonius, Vice President, Communications, K Group's building and technical trade, +358 40 709 9176, jessica.diktonius@kesko.fi Kesko Corporation DISTRIBUTIONMain news mediawww.kesko.fi

Citycon decided on a quarterly distribution

The Board of Directors of Citycon Oyj has today decided, on the basis of the authorisation by the Annual General Meeting 2018, that an equity repayment of EUR 0.0325 per share be distributed from the invested unrestricted equity fund of the company. The equity repayment will be paid to a shareholder registered in the company’s shareholders’ register maintained by Euroclear Finland Ltd on the record date for the equity repayment 21 June 2018. The equity repayment will be paid on 29 June 2018.Following the asset distribution on 29 June 2018, Citycon Oyj has distributed a total dividend and equity repayment of EUR 0.065 per share during the year 2018 and the remaining authorisation of Citycon’s Board of Directors is EUR 0.065 per share.Helsinki, 19 June 2018CITYCON OYJFor further information, please contact:Marcel KokkeelChief Executive OfficerTel. +358 40 154 6760marcel.kokkeel@citycon.comEero SihvonenExecutive VP and CFOTel. +358 50 557 9137eero.sihvonen@citycon.comCitycon is a leading owner, manager and developer of urban, grocery-anchored shopping centres in the Nordic region, managing assets that total approximately EUR 4.5 billion. Citycon is No. 1 shopping centre owner in Finland and among the market leaders in Norway, Sweden and Estonia. Citycon has also established a foothold in Denmark.Citycon has investment-grade credit ratings from Moody's (Baa2) and Standard & Poor's (BBB). Citycon Oyj’s share is listed in Nasdaq Helsinki.www.citycon.com

RhoVac’s reports positive and constructive response from the European Medicines Agency in the now completed Scientific Advice Procedure

In alignment with company’s original schedule, RhoVac initiated a Scientific Advice Procedure with EMA in March 2018, to discuss progression of company’s RV001 project into a clinical phase IIb development, and to ensure that RhoVac’s approach was in line with EMA’s guidelines and expectations. Following this, in May, RhoVac was invited to participate at the EMA’s Scientific Advice Working Party's (SAWP) meeting in London to further discuss the project. Now RhoVac has received the response which was adopted by The Committee for Medicinal Products for Human Use (CHMP) at their meeting 28 – 31 May 2018. The response given by SAWP is based on the questions and supporting documentation RhoVac submitted at the initiation of the procedure.   In summary, EMA has agreed that no further pre-clinical studies are needed to support the proposed phase IIb clinical trial development. EMA has also agreed that the company’s approach in development of a quality specification for RV001 drug candidate was in compliance with relevant regulatory guidelines. In the response relating to the proposed clinical trial, which targets the early stage of prostate cancer, immediately after radical prostatectomy, EMA agreed that there is a clear window to treat in this stage of the disease using RhoVac’s RV001 drug candidate. Finally, EMA provided valuable advice to further definition of the patient population and on inclusion criteria for the patients to be enrolled in the proposed clinical study. Comments from RhoVac´s CEO, Anders Ljungqvist -The Scientific Advice Procedure including the face to face meetings with relevant experts at EMA have been extremely valuable for RhoVac assuring us that we are now in a position to refine and progress our plans for our clinical phase IIb development. To our knowledge, there are no other drugs in development targeting this very early stage of disease progression in prostate cancer while relevant regulatory guidelines for adjuvant treatment in this stage are scarce. The comments and advice from EMA are therefore crucial for the further development of our drug candidate RV001. 

Balder will be an important partner in Väsby Entré

Fastighets AB Balder will be a so-called anchor partner in the work on Väsby Entré, i.e. will develop more than half of Väsby Entré. The decision was taken by the Municipal Council yesterday. The Municipal Council in Upplands Väsby yesterday approved a land alllocation agreement between Upplands Väsby Municpality and Balder. Consequently, Balder will be the Municipality’s anchor partner in the continued work on Väsby Entré, which is Upplands Väsby’s largest-ever urban development project.     -       Väsby Entré will be a landmark for the northern part of the County. I look forward to cooperating with Balder in order to realize Väsby Entré, says Mathias Bohman (Social Democratic Party), Chairman of the Municipal Executive Board.   As the anchor partner, Balder will be responsible for developing more than half of Väsby Entré, while other companies will be responsible for the remaining part. About one third of the planned homes will be rental apartments and two thirds with be tenant-owner’s apartments. Balder’s participation will include housing as well as premises for public services and commercial use. -       It will be extremely rewarding after all the yeas of planning to be able to realize Väsby Entré together with such a serious player as Balder, says Anne-Sophie Arbegard, Project Manager for Väsby Entré.  The station area will be developed for flexible travel and transfers involving bicycle, car, bus and commuter train. The project also includes more that 1,000 new homes in apartment buildings and premises of 30,000 square metres for shops and offices. The architectural vision, which was the result of an extensive civic dialogue, is the final project designed by the world-famous architect Zaha Hadid before her premature passing. -       We are impressed by the friendly and professional reception from Upplands Väsby. Both parties believe in taking overall responsibility and in a development that will extend far into the future, which feels very promising, says Erik Selin, CEO of Balder.  About 50 construction companies registered their interest in 2017 to participate in the development of Väsby Entré. The Municiaplity chose to enter into an advanced dialogue with 15 companies, including Fastighets AB Balder. Evaluation is continuing of the other strategic construction companies that will be chosen by the Municipality during the autumn of 2018.   During 2017 and spring 2018, Balder submitted successful tenders in respect of three major urban development projects; Rissne, Hallonbergen and now Väsby Entré.   -       We are humble about the great confidence that Upplands Väsby has placed in us. It will be particularly interesting to cooperate with the Municipality and the other companies from the industry who will complete the team. Together we are going to create something really excellent, says Erik Selin.  In producing its project concept, Balder has cooperated with the architect’s office 3XN. For more information, please contact:  Upplands Väsby Municipality/Väsby EntreProject Manager Väsby Entré, Anne-Sophie Arbegard, +46 73 910 46 29  Chairman of the Municipal Executive Bo, Mathias Bohman (S), +46 8 590 977 44 BalderCEO Erik Selin, erik.selin@balder.se, +46 706 07 47 90 orSenior Vice CEO Thorsten Åsbjer, thorsten.asbjer@balder.se, +46 706 53 39 10  In photo from left: Anne-Sophie Arbegard, projektchef Väsby Entré, Mathias Bohman, kommunstyrelsens ordförande Upplands Väsby, Erik Selin, VD Balder, Oskar Weinmar, oppositionsråd Upplands Väsby, Hillevi Engström, kommundirektör Upplands Väsby. Photographer i Oskar Kullander.    Fastighets AB Balder is a listed real estate company which shall meet the needs of different customer groups for premises and housing through local support. Balder's real estate portfolio had a value of SEK 104.1 billion (88.4) as of 31 March 2018. The Balder share is listed on Nasdaq Stockholm, Large Cap  Fastighets AB Balder (publ)PO Box 53 121, 400 15 GothenburgTel: +46 31 10 95 70Corporate Identity No. 556525-6905, Registered office Gothenburgbalder.se 

Sandvik divests its stainless wire business

Sandvik's business area Sandvik Materials Technology has signed an agreement to divest its stainless wire business to Zapp Group, a German family-owned leading supplier of advanced metal products. This completes the full scope of the divestment plan for the welding and stainless wire operations, initially announced on 17 May 2017. The deal includes the production unit in Sandviken, Sweden and the global sales organization, along with selected trademarks and patents; in total approximately 145 employees, of which the majority in Sandviken. Revenues for the stainless wire business amounted to 310 million SEK in 2017 and the enterprise value is 183 million SEK. “I am pleased that we have further consolidated the business portfolio to the core operations of Sandvik. Zapp is a focused and strong player in its field, providing a solid platform for the stainless wire business and its employees”, says Björn Rosengren, President and CEO of Sandvik. Closing of the divestment is expected in the third quarter 2018, following fulfillment of customary closing conditions.  For further information, contact Ann-Sofie Nordh, Vice President Investor Relations, tel: +46 8 456 14 94 or Martin Blomgren, Press and Media Relations Manager, tel: +46 70 577 05 49. Stockholm, 19 June 2018 Sandvik AB ----------------------------------------------------------------------------------------------------------------------------------------------- Sandvik GroupSandvik is a high-tech and global engineering group offering products and services that enhance customer productivity, profitability and safety. We hold world-leading positions in selected areas – tools and tooling systems for metal cutting; equipment and tools, service and technical solutions for the mining and construction industries; products in advanced stainless steels and special alloys as well as products for industrial heating. In 2017, the Group had approximately 43,000 employees and sales of 91 billion SEK in more than 150 countries within continuing operations. Sandvik Materials TechnologySandvik Materials Technology is a business area within the Sandvik Group and a world-leading manufacturer of high value-added products in advanced stainless steels and special alloys as well as products for industrial heating. The cutting-edge expertise is based on an integrated production platform and industry-leading metallurgy and R&D. In 2017, sales were approximately 14 billion SEK with about 6,500 employees.

ChemoTech signs Memorandum of Understanding

The aim of this clinical study is to demonstrate a probable reduction of tumor size(s) and level of pain as well as improvement of life, when patients with cutaneous and subcutaneous head and neck tumors are treated with IQWave™ D-EECT. PPUM has already received “Special Access” for IQWave™ from the authorities, which is an import license for equipment or drugs that are not yet registered in the country. PPUM is formerly known as ‘University Hospital’ is a government-funded medical institution located in Pantai Dalam, southwest corner of Kuala Lumpur, the dynamic and bustling capital city of Malaysia. It was established by Statute in September 1962 and is part of University of Malaya. The objectives of PPUM are to establish, operate and develop a medical centre of international standard and repute; and to co-operate with Faculty in providing facilities for medical education, training, research, internship and consultancy. For more information, please contact: Mohan Frick, CEO +46 (0)10-218 93 00 info@chemotech.se Scandinavian ChemoTech AB (publ) www.chemotech.se ChemoTech is a young and dynamic life science company that possesses a great medical expertise and technical knowledge. Our latest launch of IQWave™ is an innovation within electrochemotherapy, that is adapted for the treatment of different types of tumors. ChemoTech strives to contribute to a more accessible cancer care. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. The company is headquartered in Malmö, in the midst of the medical technology expansionary Öresund region.

Instalco strengthens its heating and plumbing operations in Finland with new acquisition

LVI-Urakointi was founded in 2001 and currently has 47 employees. The company offers heating and plumbing installations and ventilation works in primarily Helsinki with surrounding areas. Examples of previous assignments are heating and plumbing works at the Eira Hospital and at the latest cargo terminal of Finnair at the Helsini-Vantaa airport. For the 2017 financial year, net sales amounted to approximately EUR 9.2 million. “With LVI-Urakointi, we continue to expand in the exciting Helsinki region. The company is characterised by stable profitability and has an experienced management, and I am confident that it will fit well into the group”, says Robin Boheman, Business Area Manager Finland at Instalco. The majority of LVI-Urakointi is owned by its founder and CEO Tomi Paavola, who will remain in his role and continue leading the company. “This feels like a natural step in our development. We already have a good collaboration in place with Instalco’s other heating and plumbing company in Helsinki, which we look forward to increase further as part of the group”, says Tomi Paavola. Instalco acquires 100% of LVI-Urakointi Paavola Oy with completion today 19 June. For more informationAdrian Westman, Head of Investor Relationsphone +46 73 509 04 00, e-mail adrian.westman@instalco.se Instalco is one of the leading installation companies in the Nordic region, active in the areas of heating, plumbing, electricity, cooling and industrial solutions. We work closely with customers, offering all the advantages of a local company, along with efficient collaboration and leadership. The operations are conducted through approximately 45 leading and highly specialised local companies, with the support of a small central organisation. Instalco is listed at Nasdaq Stockholm under the ticker INSTAL. For further information, visit www.instalco.se.

Cantargia’s immuno-oncology antibody CAN04 has obtained the INN nidanilimab by WHO

Cantargia’s lead project CAN04 is investigated in the phase I/IIa CANFOUR clinical trial evaluating treatment of patients with cancer. The focus is on non-small cell lung cancer (NSCLC) or pancreatic cancer. As part of the ongoing development, WHO has reviewed Cantargia’s application for the INN, confirmed that it fulfills the requirements and selected the generic name nidanilimab for CAN04. “The CAN04 development has reached a stage with a generic name being of relevance. WHO has selected the INN nidanilimab. Cantargia will primarily use nidanilimab in future communication”, Göran Forsberg, Cantargia’s CEO says. For further information, please contact Göran Forsberg, CEOTelephone: +46 (0)46-275 62 60E-mail: goran.forsberg@cantargia.com This constitutes information that Cantargia AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 19 June 2018, at 15:00. About Cantargia Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life-threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein (IL1RAP) in leukemic stem cells. Subsequent research has also identified IL1RAP in many other forms of cancer. The company’s main project, the CAN04 antibody targeted at IL1RAP, is being studied in the CANFOUR clinical phase I/IIa study, where the primary focus is on non-small cell lung cancer and pancreatic cancer. CAN04 has two modes of action: it blocks the function of IL1RAP and stimulates the immune system to destroy tumour cells. Cantargia’s second project, currently in the research phase, is aimed at developing an IL1RAP-binding antibody that is optimised for treatment of autoimmune and inflammatory diseases. Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.

DIGNITANA RESPONDS TO AMERICAN MEDICAL ASSOCIATION DECISION REGARDING UNIQUE CPT CODE FOR SCALP COOLING

Lund, Sweden – 19 June 2018 –  Dignitana AB , world leader in clinically superior scalp cooling technology, has responded to the announcement made earlier today by the American Medical Association (AMA), on their decision to reject the company’s application to create a unique CPT® code for FDA-cleared automatic scalp cooling devices. The request, which was made at the May 2018 CPT Editorial Panel Meeting, was part of Dignitana’s efforts to provide a pathway for a more universal and standardized patient coverage method. At present, the service of scalp cooling used in conjunction with patients’ chemotherapy treatments for solid tumor cancers is not reflected in CPT nomenclature. CPT® Codes, which are designated by the American Medical Association (AMA) and used to report medical, surgical, and diagnostic procedures and services to physicians, health insurance companies and accreditation organizations, are required by insurance companies (Third Party Payers) to correctly and consistently process claims for scalp cooling. Though Third Party Payers determine covered items within a specific patient plan, the creation of a CPT® Code  provides a pathway for a more universal and standardized patient coverage method thereby providing greater access to this quality of life cancer care option nationwide. “While we are disappointed with the outcome of our request to establish a new CPT code for scalp cooling which would have simplified the process for all parties involved, we respect the AMA’s decision and will continue to provide the necessary documentation and data needed to aid in their future assessments,” said William Cronin, CEO of Dignitana AB. “This decision does not change the increasing demand for scalp cooling by patients and we remain committed to working on behalf of all cancer patients to make access to this valuable therapy option easier and more affordable.” Until recently, hair loss was deemed an inevitable side effect of chemotherapy and continues to serve as an unwelcome reminder of the disease to cancer patients and their caregivers. An estimated 10 percent of patients decline prescribed chemotherapy out of fear of losing their hair, making greater accessibility and coverage of scalp cooling a vital component of cancer care. Demand for scalp cooling grew exponentially across the U.S. following successful results from extensive, multi-center clinical trials and subsequent FDA clearances of the technology. The DigniCap® Scalp Cooling System was the first of its kind to be cleared by the FDA in 2015 for use by breast cancer patients  and in July 2017 it became the first device to receive FDA clearance for use by patients with solid tumor cancers . Dignitana will continue to work with the AMA on the complex process of creating a pathway to insurance coverage for scalp cooling and remains dedicated to its role as a market leader and advocate for improving comprehensive cancer care on a national scale. This information is information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the contact below, for publication at 1720 (CET) 19 June 2018 For more information contact: William Cronin, CEO, Dignitana AB  bill.cronin@dignitana.com +1 469 917 5555 Mikael Wahlgren, Deputy Managing Director, Dignitana AB  mikael.wahlgren@dignitana.com    +46 709 33 72 20

Hemfosa explores the conditions for conducting adirected share issue of common shares

Hemfosa Fastigheter AB (publ) (“Hemfosa” or “the Company”) has appointed ABG Sundal Collier, SEB and Swedbank to explore the conditions for conducting a directed share issue in the total amount of up to 10 million shares (the “Share Issue”) through an accelerated bookbuilding procedure, (the “Bookbuilding”). If conducted, the Share Issue will be directed towards Swedish and international institutional investors, and executed with the authorisation given by the annual general meeting held on 18 April 2018. The purpose of the Share Issue is to provide the Company with additional equity capital in a quick and efficient manner in order to utilize current business opportunities and optimise the capital structure ahead of a contemplated split of the group. The Share Issue is, among other things, subject to a resolution by the board of directors of Hemfosa, pursuant to the issue authorization given by the annual general meeting held on 18 April 2018 to issue new shares, following the close of the Bookbuilding. The Board of Directors can at any time choose to terminate the Bookbuilding and refrain from executing the Share Issue. Important information Release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions according to law and people in those jurisdictions, in which this press release has been announced or distributed, should inform themselves of and follow such legal restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Hemfosa in any jurisdiction. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed to the United States, Canada, Australia, South Africa, Japan, Hong Kong, Switzerland, Singapore, New Zealand or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations. This press release is not a prospectus. Hemfosa has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus has been prepared or will be prepared in connection with the directed new share issue. 

PAXMAN comments on AMA decision on CPT code for scalp cooling

As previously communicated by PAXMAN, the company welcomes AMA's work to introduce a CPT code for all FDA approved scalp cooling treatments. PAXMAN is not responsible for the application to the AMA, but the company has provided AMA with information when needed.  “This decision is of course disappointing, but it is not unexpected since scalp cooling is still a relatively new type of treatment in the USA. It is however important to emphasise that the AMA is now aware of the issue and is not against introducing a CPT code when the patient base is larger”, says PAXMAN’s CEO Richard Paxman. He points out that PAXMAN is experiencing significant growth in the USA, both in terms of installed systems and enrolled patients. “We have only had our FDA clearance for breast cancer since last spring, and our addressable market in the USA was multiplied just a few weeks ago as our clearance was expanded to include solid tumours. Even so, PAXMAN’s scalp cooling equipment is already available at all of the top five leading cancer centres in the USA, and we have over 289 scalp cooling systems installed and/or ordered in the country in total. We therefore expect a very strong patient enrolment in 2018, and this is of course something that the AMA will consider when they review the need for a CPT code in the future. Our Board and Management are not concerned by these news, and it should not have any effect on our current growth strategy”, says Richard Paxman. PAXMAN is engaged in multiple activities to ensure that as many patients as possible can receive reimbursement for their scalp cooling costs. In addition to supporting the introduction of a CPT code, the company is also reviewing options to introduce HCPCS codes for scalp cooling, and the company's management has an encouraging dialogue with several leading insurance companies. In addition, PAXMAN is engaged in the effort to include scalp cooling in the national cancer care guidelines in the USA, which would quickly and efficiently increase the number of patients offered access to scalp cooling.

Apple Pay comes to Nordea’s First Card customers

Offering an easy, secure and private way to pay Because time is precious! Business expenses get a makeover as Apple Pay becomes available to First Card users in the Nordics.Security and privacy are at the core of Apple Pay. When you use a credit or debit card with Apple Pay, the actual card numbers are not stored on the device, nor on Apple servers. Instead, a unique Device Account Number is assigned, encrypted and securely stored in the Secure Element on your device. Each transaction is authorized with a one-time unique dynamic security code.From the largest companies to the smallest one-person firms, everyone that has ever used a corporate card knows the challenges sometimes associated with making business purchases. Time can be lost in all sorts of administrative processes. This is even more the case if you forget your corporate card and need to use your own personal card or ask for an invoice. Now with the introduction of Nordea’s corporate First Card to Apple Pay, business payments of all kinds from travel expenses to purchasing office supplies are made easy, private and secure.Erik Zingmark, Head of Transaction Banking at Nordea, says: - We are delighted to make it easier to always use your corporate card whether you are a business traveller or making other work-related purchases. The same ease of use and convenience customers enjoy when making consumer purchases with Apple Pay can now be equally enjoyed with a corporate card.Goodbye plastic, hello conveniencePlacing both corporate and personal cards within Apple Pay gives customers the choice of making mobile payments for whatever they may be purchasing throughout the day. - Now we are closing the circle and you can use Apple Pay 24/7 for both your business expenses and consumer purchases. Apple Pay is perfect for both business and pleasure, adds Erik Zingmark. - For business travelers, every minute saved during a long day of taking taxis, planes and trains is extra time that can be used more productively elsewhere.Staying relevant- Our aim is to be more convenient and relevant for our customers and meet them where we see that digital trends are demanding new services. We can see a clear movement from plastic into mobile payments so we started with the consumer side and now it’s only natural to offer the benefits of Apply Pay to our corporate card customers as well. Our strategy is to secure that all cards are connected so it’s possible for the customer to easily choose different ways of paying. We are committed to giving our customers the best experience and Apple have been very dedicated in securing that the customer convenience is really there, notes Lars Boström, Head of Cards, Transaction Banking at Nordea.Apple Pay is easy to set up and users will continue to receive all rewards and benefits offered by credit and debit cards. In stores, Apple Pay works with iPhone SE, iPhone 6 and later, and Apple Watch.  Online shopping in apps and on websites accepting Apple Pay is as simple as the touch of a finger with Touch ID, so there is no need to manually fill out lengthy account forms or repeatedly type in shipping and billing information. When paying for goods and services on the go in apps or Safari, Apple Pay works with iPhone 6 and later, iPhone SE, iPad Pro, iPad Air 2, and iPad mini 3 and later. You can also use Apple Pay in Safari on any Mac introduced in or after 2012 running macOS Sierra and confirm the payment with iPhone 6 or later or Apple Watch, or with Touch ID on the new MacBook Pro.Read more on: http://www.apple.com/apple-pay/ For further information:Claes Eliasson, Group Communications, +46 72 141 67 12

The Children’s Climate Prize presents this year’s jury!

The prize was initiated in 2016 by Telge Energi, a company exclusively working with renewable energy sources thus taking a stand for sustainable development for more than 10 years. But Telge Energi want to do more to help save the world while also supporting others on the same journey. Therefore, the company launched the Children's Climate Prize two years ago to award a child or youth who has made extraordinary world-enhancing efforts focusing on climate and the environment. The prize was established to spotlight the climate issue from the perspective of children and young adults, with the insight that the future at stake is theirs. The winner and all finalists are selected by a jury and the winner receives diploma, a medal and 50,000 SEK. An independent jury has now been appointed and holding the gavel yet another year will be climate profile, Johan Kuylenstierna. Another member of this year’s jury is Luca Berardi, a finalist of the Children’s Climate Prize in 2016, who has since moved to Lund, Sweden. Earlier this year, Luca received Lund's environmental award for his substantial involvement in climate issues. Telge Energi's staff will be more involved in the initiative this year and a staff representative will also take part in this year's jury.  The Children’s Climate Prize Jury 2018:  Johan Kuylenstierna, Senior advisor to Stockholm Environment Institute  Micael Dahlén, writer and professor at Stockholm School of Economics  Doreen Månsson, TV personality, engaged in environmental and social causes  Luca Berardi, finalist of the Children’s Climate Prize in 2016 and recipient of Lund’s environmental award 2018  Zeinab Ismail Adem, WWF Sweden Youth  Katarina Mohlin, Board member of Telge Energi  Telge Energi-staff representative, chosen just before the jury meeting this fall  The Children’s Climate Prize takes place on November 20 - 21st. On April 23rd we started accepting applications and all contributions are easily submitted via a form on our website which can be found here >>   We’d like it if you’d follow us on social media Children’s Climate Prize on Facebook >>  Children´s Climate Prize on Twitter >>  Children’s Climate Prize on Instagram >> 

Changes in ASSA ABLOY’s Group Management

Carolina Dybeck Happe, CFO and Executive Vice President of ASSA ABLOY has decided to leave the company for a position outside the Group. She will be leaving at the end of December 2018 and the process to find her successor has been initiated. “During her time as CFO of ASSA ABLOY Carolina Dybeck Happe has been instrumental in the Group’s growth and acquisition strategy. She has successfully initiated and implemented a digital transformation program enabling the company’s growth in digital services to our customers as well as improving the company’s efficiency by streamlining the information flow within sales, supply chain, R&D and financial and administration services,”says Nico Delvaux, President and CEO ASSA ABLOY. “I would like to take the opportunity to thank Carolina for her long and valuable time within the ASSA ABLOY Group, and I wish her great success in her new position,” Nico Delvaux concludes.  For more information, please contact:Nico Delvaux, President and CEO, tel. no: +46 8 506 485 82Holger Lembrér, Investor Relations Officer, tel. no: +46 8 506 485 76Ann Holmberg, Head of Group Communications, tel. no: + 46 8 506 485 54 This is information that ASSA ABLOY AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CET on 20 June 2018. About ASSA ABLOYASSA ABLOY is the global leader in door opening solutions, dedicated to satisfying end‑user needs for security, safety and convenience. Since its formation in 1994, ASSA ABLOY has grown from a regional company into an international group with about 47,500 employees, operations in more than 70 countries and sales of SEK 76 billion. In the fast-growing electromechanical security segment, the Group has a leading position in areas such as access control, identification technology, entrance automation and hotel security.

Tieto: new comparison figures based on business transfers

Tieto Corporation        STOCK EXCHANGE RELEASE        20 June 2018, 9.00 EET Tieto has implemented internal business transfers that help the company capture consulting-driven market opportunities as well as further drive customer value. As from 1 April, business transfers from Technology Services and Modernization to Business Consulting and Implementation include enterprise application-related business for cloud-born applications, integration consulting and Value Networks as a related solution. Annual sales of the transferred businesses amount to around EUR 37 million. In addition, Tieto's Financial Digital Channels business (previously part of the Industry Solutions service line), with sales of EUR 11 million, was transferred to Business Consulting and Implementation on 1 May. Other business transfers are smaller in size. The business transfers will be included in the second-quarter interim report for 2018 to be published on 20 July. The restated comparison figures are provided in the attachment and the figures are also available in Excel format at www.tieto.com/Investors . For further information, please contact: Tanja Lounevirta, Head of Investor Relations, tel. +358 50 321 7510, tanja.lounevirta (at) tieto.com TIETO CORPORATION DISTRIBUTIONNASDAQ HelsinkiPrincipal Media Tieto aims to capture the significant opportunities of the data-driven world and turn them into lifelong value for people, business and society. We aim to be customers’ first choice for business renewal by combining our software and services capabilities with a strong drive for co-innovation and ecosystems.  Headquartered in Finland, Tieto has over 14 000 experts in close to 20 countries. Tieto’s turnover is approximately EUR 1.5 billion and shares listed on NASDAQ in Helsinki and Stockholm. www.tieto.com 

Wärtsilä introduces new hybrid solar PV and storage solution

The technology group Wärtsilä introduces a new hybrid solar PV and storage solution. Wärtsilä Hybrid Solar integrates solar PV generation and storage to deliver a true “renewables as baseload” solution that is not only climate-friendly, increases resilience and efficiencies but can be supported by a power producer’s existing grid infrastructure. Hybrid Solar will allow utilities to transform the efficiency and reliability of their systems with an adaptable solar PV power plant that can support its baseload needs,” said Magnus Miemois, Director, Hybrids, Wärtsilä Energy Solutions. “As our global energy ecosystem evolves, Hybrid Solar represents a ground-breaking approach to electricity production and power generation.” The IEA estimates  that by 2040, total global generation capacity will increase by 60 percent, and renewable energy sources, like solar, wind and hydro, will make up more than 45 percent of that total. As the world moves towards 100% renewable energy, utilities, independent power producers (IPPs) and other energy providers are motivated to harness its potential. A critical component in maximising the value of the hybrid solution is the software and controls platform that optimizes its performance. Greensmith Energy, a Wärtsilä company, develops and deploys the GEMS platform , now in its fifth-generation. GEMS enables intelligent energy applications that focus on monitoring and operating energy storage power plants and hybrid power plants formed by energy storage, thermal generation, and renewable sources. GEMS ensures system optimization of both energy storage and generation assets through changes in market conditions and rate structures – effectively "future-proofing" energy storage investments for both power developers and regulated utilities. This is just the latest hybrid energy solution offering Wärtsilä has brought to the market. Most recently, Wärtsilä delivered a 15 MW solar PV hybrid power plant  – the largest in the world – to Essakane Solar SAS in Burkina Faso, which operates with 55 MW Wärtsilä thermal power plant. The solar PV plant and the engine power plant are now controlled and operated in synchronisation, thus forming the largest engine-solar PV hybrid power plant in Africa. The ability to control and optimise the usage of engines and solar power will enable the mine to decrease its fuel consumption by approximately 6 million litres per year and to reduce its annual CO2 emissions by 18,500 tons. Wärtsilä introduces the new Hybrid Solar at Intersolar Europe 2018 , the world’s leading exhibition for the solar industry, at Messe München exhibition center in Munich. Wärtsilä, located in Hall B2, booth #154, will host an event to mark the launch of Hybrid Solar on Wednesday, 20 June from 14:00-15:00. Intersolar attendees and members of the media are invited to attend. For more information, please contact: Magnus MiemoisDirector, Hybrid Energy SolutionsWärtsilä Energy SolutionsTel: +358 10 7091682magnus.miemois@wartsila.com Lisa MagnusonSenior Vice President, Global MarketingGreensmith Energy – a Wärtsilä CompanyTel: +1 (415) 531 9199lisa.magnuson@greensmithenergy.com Wärtsilä Energy Solutions in briefWärtsilä Energy Solutions is a leading global energy system integrator offering a broad range of environmentally sound solutions. Our offering includes ultra-flexible internal combustion engine based power plants, utility-scale solar PV power plants, energy storage & integration solutions, as well as LNG terminals and distribution systems. The flexible and efficient Wärtsilä solutions provide customers with superior value and enable a transition to a more sustainable and modern energy system. At the end of 2017, Wärtsilä had 67 GW of installed power plant capacity in 177 countries around the world.https://www.smartpowergeneration.com/  Wärtsilä in briefWärtsilä is a global leader in smart technologies and complete lifecycle solutions for the marine and energy markets. By emphasizing sustainable innovation, total efficiency and data analytics, Wärtsilä maximizes the environmental and economic performance of the vessels and power plants of its customers. In 2017, Wärtsilä's net sales totaled EUR 4.9 billion with approximately 18,000 employees. The company has operations in over 200 locations in more than 80 countries around the world. Wärtsilä is listed on Nasdaq Helsinki.https://www.wartsila.com/ 

Tikkurila launches a new high-performance all-seasons epoxy primer for Protective Coatings

The volume solids content of Temacoat HS-F Primer is 80%, so the paint has a lower VOC value compared to conventional epoxy primers. It also provides shorter drying and recoating times even at low temperatures (down to -10°C), which is a considerable advantage. Temacoat HS-F Primer can be used all year round, expanding the geographic area of application. This high-performance primer enables a wide range of film thicknesses in one layer, which makes the painting process of complex structures easier. – Temacoat HS-F Primer is developed for the demanding, long-term protection of steel. Compared to traditional primers, it dries and cures very fast even at low temperatures typical for Northern Europe. It is truly a time-saving solution: since it is over-coatable after only two hours, you can get the job done in one day, says Michael Aamodt, Group Business and Portfolio Development Director at Tikkurila Oyj. Temacoat HS-F Primer at a glance ·All-seasons product (-10°C – +40°C) ·Fast drying and curing especially at low temperatures ·80% volume solids ·Short overcoating time (2 h) with polyurethane topcoat ·Wide film thickness range ·Excellent adhesion to steel, aluminum and galvanized steel ·Low VOC (200 g/l) ·High corrosion resistance ·Easy application with airless spray and brush ·Long max overcoating interval Download the Temacoat HS-F Primer brochure  Further information: Tikkurila GroupMichael AamodtBusiness & Portfolio Development Director, Protective and Industrial CoatingsTel. +47 22 80 32 90, Mobile +47 47 41 98 48Email michael.aamodt@tikkurila.com

Evolution to install Dual Play Roulette for Casino Malta

The Dual Play table, set within a five HD camera rig to allow on-premise and online players to play together at the same table, is expected to go live in Q3 this year. It will be located on the main gaming floor and will open 24 hours a day, seven days a week. Operated by Olympic Entertainment Group, the leading provider of gaming services in the Baltic States, Casino Malta was established in cooperation with Eden Leisure Group, the Maltese hotel and entertainment enterprise. The casino in St. George’s Bay, St. Julian’s, boasts 285 slot machines, 29 table games and Las Vegas style entertainment. Explaining the decision to select Evolution Dual Play, Simon De Cesare, CEO of Eden Leisure Group, said: “Evolution has an enviable track record and reputation of working with the leading land-based casinos to deliver customised, truly convergent solutions. We wanted our players to be able to play at one of their favourite Casino Malta Roulette tables even when they are not able to visit our casino in person or be at the actual table. Evolution Dual Play Roulette was the go-to option to enable that level of extended service and the customisation flexibility we required.” De Cesare added: “Just as importantly, Evolution Dual Play is a convergence solution that works as part of the existing set-up and procedures of our land-based operations.” James Stern, Evolution’s Director of Business Development & Land-based Sales, commented: “We are delighted to be working with Casino Malta for the first time. Casino Malta was keen to extend the ability to play at their land-based venue to a much wider audience. Given the popularity of Malta as a holiday and short-break destination, that wider audience will include, of course, the very significant number of ad hoc players who play at the casino when visiting Malta. Now, following the installation of the Dual Play table, those players will be able to continue to play at Casino Malta when they return home.”

Alfa Laval wins another offshore order, value SEK 65 million

The order comprises offshore pumping systems for injection of water into the production wells in order to optimize the extraction of oil. “Our reliable and proven pumping systems meet the offshore industry’s high demands when it comes to safety and quality. This order, the second within a short period of time, is a confirmation of that,” says Peter Leifland, President of the Marine Division. Did you know that… Framo has been the recognized leader in pumping systems for the marine industry for more than half a century and it became part of the Alfa Laval Group in 2014? About Alfa Laval                                                                                                         Alfa Laval is a leading global provider of specialized products and engineering solutions based on its key technologies of heat transfer, separation and fluid handling. The company’s equipment, systems and services are dedicated to assisting customers in optimizing the performance of their processes. The solutions help them to heat, cool, separate and transport products in industries that produce food and beverages, chemicals and petrochemicals, pharmaceuticals, starch, sugar and ethanol. Alfa Laval’s products are also used in power plants, aboard ships, oil and gas exploration, in the mechanical engineering industry, in the mining industry and for wastewater treatment, as well as for comfort climate and refrigeration applications. Alfa Laval’s worldwide organization works closely with customers in nearly 100 countries to help them stay ahead in the global arena. Alfa Laval is listed on Nasdaq OMX, and, in 2017, posted annual sales of about SEK 35.3 billion (approx. 3.6 billion Euros). The company has about 16 400 employees. www.alfalaval.com  For more information please contact:Peter TorstenssonSenior Vice President, CommunicationsAlfa LavalTel: + 46 46 36 72 31Mobile: +46 709 33 72 31Gabriella GrotteInvestor Relations ManagerAlfa LavalTel: +46 46 36 74 82Mobile: +46 709 78 74 82

Pihlajalinna lowers its 2018 profitability guidance

Pihlajalinna Plc             Stock exchange release            20 June 2018 at 9:30 Pihlajalinna lowersits 2018 profitability guidance Pihlajalinna lowers its previously published 2018 profitability guidance for the Group. Pihlajalinna now estimates that the Group’s adjusted EBIT will be below adjusted EBIT of 2017. Pihlajalinna does not make any changes to its outlook for 2018 revenue, i.e. Pihlajalinna’s consolidated revenue is expected to increase clearly from 2017 level especially due to M&A transactions. Pihlajalinna develops its business operations in line with the Group’s strategy, which has required both structural renewal and geographical expansion during the first half of the year. The structural change will take longer than expected and this has an effect on profitability also during the remaining part of the year. ”The first part of the year has been a time of big changes and new beginnings in the company, and the operative performance has been weaker than expected. Despite the weak beginning, we still believe that the planned measures, reforms and new services will strengthen our profitability during the rest of the year. They will nevertheless not be sufficient enough to raise the adjusted profit to last year’s level or above it”, says Pihlajalinna’s CEO Joni Aaltonen. The revised outlook for 2018: Pihlajalinna’s consolidated revenue is expected to increase clearly from 2017 level especially due to M&A transactions. Adjusted EBIT is expected to remain below 2017 level. The previous outlook for 2018 (published on 13 February 2018): Pihlajalinna’s consolidated revenue is expected to increase clearly from 2017 level especially due to M&A transactions. Adjusted EBIT is expected to improve compared to 2017. In the financial year 2017, revenue was EUR 424.0 million and the adjusted EBIT was EUR 20.0 million. Pihlajalinna will publish its January–June result on 16 August 2018. Pihlajalinna Plc

Million homes programme houses become self-sufficient in energy using PowerCell’s fuel cells

Gothenburg, Sweden, June 20, 2018 The English version is an in house-translation. In case of any discrepancy, the Swedish text will prevail. The municipal housing company Vårgårda Bostäder, together with Nilsson Energy, is currently working on making several houses of the million homes programme self-sufficient on renewable energy. The properties are owned by the municipal housing company Vårgårda Bostäder, while Nilsson Energy is responsible for systems and integration. The first house is now being renovated and the ordered fuel cell system will be used there. In total, six houses with 29 apartments each will be renovated, and the plan is to install fuel cells in each house. The hydrogen will be stored in a building separated from the residential buildings. The houses are initially two-story buildings but are now being expanded with a third floor to accommodate more apartments and new roofs optimized for the use of solar cells. At the same time, the houses are being made more energy-efficient. The energy that is not used during the summer will be converted to hydrogen and stored. In the winter, the stored hydrogen will be used to run fuel cells which will generate both electricity and heat. The houses will become fully self-sufficient in electricity and heat. "This is a very exciting project that in a very tangible way shows the huge potential and benefits of hydrogen-fuelled fuel cells," Per Wassén, CEO of PowerCell, said. "These houses will produce all the energy they need and will become off grid, that is, disconnected from the grid and completely self-sufficient in electricity and heat. Increased domestic production of hydrogen by means of solar and wind energy, together with fuel cells, could create a society without any negative impact on our environment and our climate. This is technology that truly can help save our planet.” The work of rebuilding the million homes program houses in Vårgårda has already started and the first house is expected to be ready for occupancy during autumn-winter. The houses in Vårgårda are not the only ones that will be self-sufficient in energy using hydrogen and fuel cells. PowerCell has already delivered a fuel cell system to Skellefteå Kraft’s Zero Sun Project. Zero Sun is a house that has been specifically designed and built for the use of hydrogen and fuel cells. Also, this house will be completely self-sufficient in energy using the sun and with hydrogen as an energy carrier. Despite being built in the northern part of Sweden, this house will produce enough energy during the summer to cover the need for heat and electricity during the cold and dark winter months. About PowerCell PS-5 PowerCell PS-5  has been developed to meet the need to generate electricity on an environmentally friendly, silent and reliable basis. The system can be used as a back-up power generator for telecom and traffic systems, but also as a generator for buildings and households. PowerCell PS-5 is available in three versions and facilitates increased use of renewable energy, if it is integrated with e.g. solar panels. The system is based on the PowerCell S2  robust fuel cell stack.

TagMaster has received a significant order for the new RFID RailTag

Press release, Stockholm, Sweden, June 20, 2018 TagMaster, the leading supplier of advanced sensor systems for Smart Cities within Traffic and Rail Solutions has received a significant order for the new RFID RailTag to be used in London Underground. The new RailTag is an evolution of the successful MarkTag HDS FP with a proven track record in numerous CBTC Metro installations worldwide. The Marktag HDS FP has been sold in numbers of tens of thousands during the last 12 years. The new RailTag is designed to have a 20 year expected Service Life in CBTC applications and by this it addresses the increased need of availability of the tracks in the most heavily trafficked Metro Systems around the globe. Since it is fully compatible with the MarkTag HDS FP it can be used in existing CBTC installations without any further adjustments of the RFID Radio systems on the vehicles. The London Underground upgrade is an essential part of Transport for Londons effort to cope with the capitals population growth by a projected 1-2 million people over the next 15 years The products will be delivered during 2018. ” This order confirms that our ambition that, together with Balogh, become a stronger supplier within Rail Solutions is clearly materializing. We together have a wider product offering and we will together become a true leading actor in train signaling” says Jonas Svensson, CEO, TagMaster. For further information please contact: Jonas Svensson, CEO, +46 8-6321950, jonas.svensson@tagmaster.com   About TagMaster TagMaster is an application driven technology company that designs and markets advanced sensor systems and solutions based on radio & vision technology (RFID, Radar & ANPR) for demanding environments. Business areas include Traffic Solutions and Rail Solutions sold under the brands TagMaster, CitySync, Balogh, CA Traffic and Magsys with innovative mobility solutions in order to increase efficiency, security, convenience and to decrease environmental impact within Smart Cities. TagMaster has dedicated agencies in the US and in China and exports mainly to Europe, The Middle East, Asia and North America via a global network of partners and, systems integrators. TagMaster was founded in 1994 and has its headquarters in Stockholm. TagMaster is a public company and its shares are traded on First North stock exchange in Stockholm, Sweden. TagMasters certified advisor is Erik Penser Bank. www.tagmaster.com

Gasum diversifies services by acquiring Enegia’s energy market services

Gasum has signed an agreement with Enegia to acquire Enegia’s energy market services business. The transaction covers the shareholdings of Enegia Consulting Oy, Enegia Portfolio Services Oy and intStream Oy. The transaction is anticipated to be completed during August 2018. Customers of Enegia energy market services business include energy companies, industry and the public sector. Energy market services employ around 35 professionals in energy sourcing and sales and in emissions trading and green certificates. Enegia’s energy market services personnel will transfer to Gasum when the transaction is closed. Energy market services will continue its business and service provision to current customers. Gasum’s aim with the transaction is to expand service provision to the natural gas market and throughout the company's operating area in the Nordic countries. ”The energy sector and gas market are changing rapidly. The competencies of Enegia’s experts will diversify and strengthen Gasum's service mix. The acquisition will enable us to offer more comprehensive services to our current customers and lead the way in the energy sector. It will also provide us with an excellent platform for the development of our product selection in the future by expanding our services geographically as well as by launching new services also in the gas market,” says Gasum CEO Johanna Lamminen.  ”The transaction will make Enegia an EnerKey-driven expert in energy management. We’re happy that Gasum as the new energy market services owner will strengthen the further development and expansion of this business as well,” says Enegia Group Oy Managing Director Kalle Ahlstedt.

Cognosec completes acquisition of ITWAY’s Cyber Security Value Added Distributor interests in Turkey and Greece

Cognosec AB (publ) (“Cognosec”), (Nasdaq:COGS OTCQX:CYBNY), a leading provider  of cyber security resilience with operations in Europe, Africa and the Middle East, signs Share Sale and Purchase Agreement (“SPA”) with ITWAY S.p.A. (“ITWAY”), a public company listed on the stock exchange managed by Borsa Italiana S.p.A. (“ITW.MI”), to acquire its Turkish and Greek cyber security product Value Added Distributors, subject to usual closing conditions.   Cognosec today announces the signing of a SPA related to the acquisition by Cognosec AB of 100% of the shares in ITWAY HELLAS SL SA & ITWAY TURKYIE LTD with aggregate revenues in 2017 of €26m* and EBITDA of €1.9m resulting in a Cognosec AB combined 2017 pro-forma revenue basis of €44m* The total consideration payable by Cognosec for the transaction is €10m consisting of €2m in cash with the balance made up of €8m in Cognosec AB new issue shares. The share consideration will be satisfied by the issue of 16,666,666 new shares resulting in 278,958,409 issued shares from 262,291,743 previously and a dilution of 6.35%. No external debt has been required to complete this transaction. The sale by ITWAY of the Value Added Distribution (VAD) businesses in Greece and Turkey completes the divestment programme of their VAD businesses. The Greek business, headquartered in Halandri, Athens, is the sole distributor for market-leading cyber brands including Check Point, RSA & McAfee and generated around 30% of the combined businesses’ revenues in the last financial year. The Turkish business, headquartered in Istanbul, Turkey, generates around 70% of the combined businesses’ revenues and counts CyberArk, Algosec and Rapid7 amongst its sole distributor relationships. Between them, the businesses employ 23 full time personnel. Both organisations have evidenced strong growth records in their respective geography and are both profitable and balance sheet positive. The acquisition of these businesses complements the recent acquisitions made by Cognosec already established in key synergistic geographies that both support and complement Cognosec’s existing geographical and technological infrastructures. The acquisition of the ITWAY businesses will also improve Cognosec’s competitive advantage especially within further geographical footholds for aggressive expansion. The transaction, as expected and previously announced, closed in Q2, 2018. Kobus Paulsen, Chairman of Cognosec commented – “It is with great pleasure that we welcome the ITWAY businesses to the Cognosec Family. Andrea and his Teams in Greece and Turkey have built remarkable cyber businesses that have shown consistent CAGRs of 20% over the past few years. They have built impeccable reputations and strong, loyal and ever expanding customer bases. I am also sincerely looking forward to working closely with Andrea, moving forwards, as a key Strategic Advisor to Cognosec AB where, with his many years cyber-specific experience, he will assist me and my Teams in identifying profitable opportunities for both organic and, merger & acquisition led growth.” G. Andrea Farina, Chairman and CEO of ITWAY said: "We believe that Cognosec is the best option for the future of Value Added Distribution operations in Greece and Turkey. The clever vision of Kobus and the deep knowledge of the cybersecurity market of Cognosec AB, together with the highly ITWAY-relevant roles & footprints in the Greek and Turkish markets represent an exceptionally strong and consistent basis for both growth and leadership in the future. Meanwhile, we will also continue to strengthen our cooperation with Cognosec AB in our common development growth strategies.” 

NCC to construct office and retail complex in Tampere, Finland

The building will be located on an excellent spot right next to the Ratina shopping center. Total area will be about 13 800 square meters of net floor space. “We are happy to start this project and the construction work with NCC. The location of the new office and retail complex is excellent with very good services nearby, and will increase the appeal of the Ratina area even more,” says says Ossi Hynynen, CIO, Property Investments at Property Development at Sponda Plc. The new building will be environmentally certified under BREEAM or LEED. Whichever the certification will be, energy efficiency will be one of the focus areas in the building. In addition to sustainability another important criterion for Sponda Plc is the convertibility of spaces. This will be considered in the planning and construction so that the premises will be as flexible and easily convertible as possible to suit different purposes and end users. NCC aims to start construction in autumn. The construction phase will last about 1,5 years and the goal is to be ready in spring 2020. “It’s great to get a chance to build on such a unique location in Tampere. The long-standing relationship we have with Sponda and our decade-long experience from similar construction projects provide a great recipe for making this building a success, says Mika Soini,” Head of NCC Building Finland. The order will be registered during the second quarter in business area NCC Building.

Interview with Gun-Britt Fransson, new Chairman of the Board in Follicum

This has been reflected in my over 30-year career in research-leading positions in pharmaceuticals, food and biotechnology. I have held various research-leading positions in KabiPharmacia, within Procordia and Orkla Foods, as well as in Probi AB, a research-based biotechnology company where I acted as Vice President R&D until March this year, and also, for a year, acted as CEO. Another research-based company where I worked as the CEO for 6 years was Alligator Bioscience AB, active in early drug development just like Follicum. In addition to my operational work, I have for the past 25 + years acted as board member and chairman of the board in both small and larger companies, foundations and universities. Examples include Bioinvent, Teknikbrostiftelsen i Lund and Malmö University. Why did you join Follicum as a Board Member?I see Follicum as an exciting small company with a big potential. The company has already created interesting and promising data in the areas where it is active, starting within hair growth, and continuing within diabetes. There is a thorough plan laid out for the coming work and a number of opportunities can be seen for the future. The company has furthermore succeeded in attracting highly skilled employees with a great commitment, which I believe is crucial to a company at this stage of development. The very close relationship with university researchers also ensures an influx of new knowledge and allows the company to stay small, limiting the cost structure, something that is a significant advantage in the phase where Follicum is today. To summarize, I see an exciting company with a high possibility to succeed with its plans. What expertise will you bring to the Follicum Board?I believe that my experience in strategic management and leadership of research-intense companies will be of value for Follicum. I also believe that the combination of scientific understanding and the ability to translate, communicate and commercialize science that I have acquired during my career, is of high importance to a research-based company in the phase where Follicum is at today. My long experience of board assignments, of strategic planning, organization and motivation of employees should also be of benefit for the activities in the board as well as to the business itself. In addition, I have, during the years built an extensive network of professionals in various research areas and industries, that can be of use when helping to guide Follicum into the future. For further information, please contact:Jan Alenfall – CEO, Follicum ABTelephone: +46 (0)46 - 19 21 97Email: info@follicum.com About Follicum ABFollicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, the drug candidate FOL-014 has demonstrated an increase in insulin release in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. www.follicum.com 

Anders Nyström new President and CEO of Bulten

Anders Nyström is a mechanical engineer with supplementary education in leadership and economics. He has extensive international experience from the automotive industry and has previously held several leading positions within, amongst others Kongsberg Automotive, Volvo Cars and Ford Motor Company. Anders joins Bulten from IAC Group where he has been Vice President Commercial since 2018. “The Board is delighted with the appointment of Anders Nyström who brings solid experience and knowledge of the automotive industry to Bulten. With his background and leadership I am convinced that he will be able to further develop the company and take it to new successes”, says Ulf Liljedahl, Chairman of the Board. “Bulten is an extremely well-managed company with a very strong platform and position as supplier and partner of fastener solutions to the global automotive industry. I look forward to taking part in the continued journey that this exciting company faces,” says Anders Nyström, incoming President and CEO. Anders takes over as President and CEO after Tommy Andersson, who retires after nineteen successful years at Bulten as previously announced on October 26, 2017. Tommy Andersson will remain President and CEO up to and including February 7, 2019. For further information, please contact: Ulf Liljedahl, Chairman of the Board, Bulten ABtel: +46 40-660 30 00, e-mail: chairman@bulten.com Kamilla Oresvärd, SVP Corporate Communicationstel: +46 70-520 59 17, e-mail: kamilla.oresvard@bulten.com This information is information that Bulten AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the SVP Corporate Communications set out above, at 11:00 CET on 20 June, 2018. Bulten is one of the leading suppliers of fasteners to the international automotive industry. The company’s product range includes everything from customer-specific standard products to customized special fasteners. The company also provides technical development, line-feeding, logistics, material and production expertise. Bulten offers a Full Service Provider concept or parts thereof. The company was founded in 1873, has some 1,400 employees in eight countries and head office in Gothenburg. The share (BULTEN) is listed on Nasdaq Stockholm. More information can be found at www.bulten.com.

HSwMS Gotland Relaunched After Mid-Life Upgrade

Strategically important in a nation’s defence, submarines are designed to operate for decades in challenging environments whilst remaining adaptable given the advance of technology and future threats. To keep them at the cutting-edge of technology, Sweden’s Gotland-class submarines have received regular overhauls and upgrades during their operational life. Due to this MLU, the Gotland submarine has capabilities that will be found in the next generation of Swedish submarines, the A26.    “The relaunch of Gotland is an important milestone in the evolutionary development of Swedish submarines. After a comprehensive upgrade, integrating the latest generation of important systems such as the Stirling engine, modern sensors and new management functions, Gotland is almost a new submarine, ready to take on missions around the world,” says Gunnar Wieslander, Senior Vice President, head of business area Kockums at Saab. The Gotland was designed and built by Kockums in Malmö in the early 1990’s and commissioned in 1996. The mid-life modification consists of upgrades of onboard systems and technology, sustaining the submarine’s operability, and ensuring service to Sweden beyond 2025. The upgrade process entails many important systems, such as the Stirling Air Independent Propulsion (AIP). Sensors and management system are replaced with updated versions. Even the traditional optical periscope is replaced with a new optronic mast. This updated version of the Gotland will pave the way for the most modern AIP submarine under production today: the A26 for the Royal Swedish Navy. More than 20 systems on-board the new Gotland-class will be implemented in the A26. The MLU of Gotland therefore contributes to the test and qualification of some of the innovative solutions to be implemented in the future Swedish A26 submarine class. The relaunch ceremony of the Gotland took place in Karlskrona on June 20. Please visit saab.com/submarineevolution for interviews, images and infographics regarding the relaunch. Facts about the MLU of Gotland Length overall                       62 m Beam                                    6.2 m Displacement                       1580 tons (surfaced) Weapons                              Torpedoes, bow tubes, swim-out Propulsion                            Single-shaft, diesel-electric and Stirling AIP Endurance                            Weeks (submerged) Hull                                       Single pressure hull, two pressure tight compartments Crew                                     25 The Building Contract          Modifications of two submarines, verification incl. Set to Work (STW), Harbour Acceptance Test (HAT), Sea Acceptance Test (SAT), training, documentation, spares and upgrade of land-based Training Facility                                              Delivery end of 2018 and 2019 respectively Mid-life Upgrade                   Submarine is cut open in the mid-tank section, adding a new section including sea water cooling, fresh water cooling, water chiller units Improved capabilities;          Stirling AIP MkIII, Masts, Sensors, Communication, Special Ops New rules and regulations:  IMO, Security, Crew Comfort End-of-life and obsolescence issues: Combat and Ship’s Management Systems Experience based improvement For further information, please contact: Saab Press Centre, +46 (0)734 180 018 presscentre@saabgroup.com www.saabgroup.com  www.saabgroup.com/YouTube  Follow us on twitter: @saab  Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs. 

Allgon AB (publ) publishes prospectus in connection with fully guaranteed share rights issue of approximately SEK 127 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. On 18 June 2018, the Extra General Meeting in Allgon AB (publ) (”Allgon” or the ”Company”)  resolved to conduct a rights issue with preferential rights for existing shareholders (the “Rights Issue”). The Board of Directors has, in connection thereof, prepared a prospectus which today has been approved and registered by the Swedish Financial Supervisory Authority (the “SFSA”) and published on the Company’s web page, www.allgon.se. The prospectus has been prepared in connection with the Rights Issue and has today been approved and registered by the SFSA. The prospectus is available on the Company’s web page (www.allgon.se) and ABG Sundal Collier’s in the section “Ongoing transactions” (www.abgsc.com). The prospectus will, within a few days, also be available on the SFSA’s web page (www.fi.se). For full information regarding the Rights Issue, please refer to the prospectus. Time table for the Rights Issue  +-------------------------------------------------------+--------------------+|Event |Date |+-------------------------------------------------------+--------------------+|Prospectus published on the Company’s web page |20 June 2018 |+-------------------------------------------------------+--------------------+|Subscription period starts | 21 June 2018 |+-------------------------------------------------------+--------------------+|Trading in subscription rights commences | 21 June 2018 |+-------------------------------------------------------+--------------------+|Trading in BTA’s commences | 21 June 2018 |+-------------------------------------------------------+--------------------+|Trading in subscription rights ends |5 July 2018 |+-------------------------------------------------------+--------------------+|Subscription period ends | 9 July 2018 |+-------------------------------------------------------+--------------------+|Announcement of preliminary outcome in the Rights Issue| 11 July 2018 |+-------------------------------------------------------+--------------------+|Announcement of final outcome in the Rights Issue | 13 July 2018 |+-------------------------------------------------------+--------------------+|Trading in BTA’s ends | 18 July 2018 |+-------------------------------------------------------+--------------------+|Trading in new shares commences | Around 20 July 2018|+-------------------------------------------------------+--------------------+|Delivery of new shares | Around 24 July 2018|+-------------------------------------------------------+--------------------+ Advisors ABG Sundal Collier has together with Redeye acted as financial advisors to the Company and Baker McKenzie is the legal advisor to the Company in connection with the Rights Issue. For more information and contact: Johan Hårdén, CEO Allgon ABjohan.harden@allgon.se+46 73 385 92 19  About Allgon  Allgon is a corporate group with a strong entrepreneurial culture. Our focus is on giving value to our shareholders by developing and acquiring top businesses with a global customer base within digitalization and IoT. Allgon (ALL B) is trading on Nasdaq First North Stockholm with FNCA Sweden as certified adviser. Our specialist companies deliver a wide range of services for advanced industrial IoT equipment, digital communications systems, cloud-based infrastructure and wireless solutions for demanding environments. Our global customer base is within automotive, mobile and telecom, transport, construction and broadcasting sectors. For more information: www.allgon.se. Important information  The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Allgon in any jurisdiction, neither from Allgon nor from someone else. Any investment decision in connection with the Rights Issue must be made on the basis of all publicly available information relating to the Company. Such information has not been independently verified by the financial advisors. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zeeland, Singapore, South Africa,  the United States or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations. This press release is not a prospectus for the purposes of Directive 2003/71/EC (the “Prospectus Directive”) and has not been approved by any regulatory authority in any jurisdiction. A prospectus regarding the Rights Issue described in this press release has been approved and registered by the SFSA and is available at Allgon's website. In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it. Forward-looking statements This press release contains forward-looking statements that reflect the Company’s intentions, beliefs, or current expectations about and targets for the Company’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “will”, “should”, “could”, “aim” or “might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release. Information to distributors  Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (“MiFID II”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the “MiFID II Product Governance Requirements”), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any “manufacturer” (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in Allgon have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the “Target Market Assessment”). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in Allgon may decline and investors could lose all or part of their investment; the shares in Allgon offer no guaranteed income and no capital protection; and an investment in the shares in Allgon is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the share issue. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in Allgon. Each distributor is responsible for undertaking its own Target Market Assessment in respect of the shares in Allgon and determining appropriate distribution channels. 

Invitation to Ahlsell's Capital Markets Day

Ahlsell, the leading Nordic distributor of installation products, tools and supplies, will host a Capital Markets Day (CMD) for institutional investors, analysts and financial media on September 4, 2018. The CMD will be held in Stockholm and conducted in English. The day starts at lunchtime and concludes with an optional dinner in the evening. During the CMD, Johan Nilsson, CEO, Kennet Göransson, CFO, and other members of the Group Management will provide further insights into Ahlsell’s strategy for profitable growth. We will cover topics such as market exposure and resilience, profitability development, organic growth initiatives in our main markets and an M&A-deep dive. Please register no later than August 24 by using this link: www.ahlsell.com/cmd2018. Please note that the number of participants is limited and that institutional investors, analysts and financial media are prioritized to participate. For further information please contact:Karin Larsson, Head of IR and external communications+46 8 685 59 24, karin.larsson@ahlsell.sePetra Aldén, Senior Executive Assistant+468 685 70 68, petra.alden@ahlsell.se Ahlsell is the Nordic region’s leading distributor of installation products, tools and supplies for installers, construction companies, facility managers, industrial and power companies and the public sector. The unique customer offer covers more than one million individual products and solutions. The Group has a turnover of over SEK 28 billion and about 97 percent of revenue is generated in the three main markets of Sweden, Norway and Finland. With about 5,600 employees, more than 230 branches and three central warehouses, we constantly fulfil our customer promise: Ahlsell makes it easier to be professional!

BioGaia appoints new Managing Director

Previously, Isabelle Ducellier has held a number of senior international positions within the Pernod Ricard Group for 20 years, mainly within sales and marketing. She completed her career there as CEO and Board member of Pernod Ricard Sweden and successfully led the integration of Vin & Sprit AB into the Group. After that, she has been a partner and consultant at McKinsey Sweden, among other things in the fields of advanced digital marketing, mergers and acquisitions. In addition to a Master's degree in International Marketing Isabelle has also completed Executive MBA programs at both Harvard and INSEAD. "We are very pleased that we have been able to recruit Isabelle. She has extensive knowledge and a solid international experience of leading positions in sales and consumer marketing, which has become an increasingly important component of our business development. Isabelle also has the intellectual curiosity and energy needed to be able to embark on the advanced research in our business areas including the microbiome field. Here, her experiences from the Swedish Childhood Cancer Fund are also well-suited," says Peter Rothschild, Chairman of the Board at BioGaia. "I am very happy about this appointment and look forward to contributing with my special skills to BioGaia’s already very successful business model,” says Isabelle Ducellier, future Managing Director of BioGaia. As previously announced, BioGaia's current Managing Director terminates his employment June 30. From this point until November 5, when Isabelle can leave her assignment at the Swedish Childhood Cancer Fund, Sebastian Schröder is Acting Managing Director. This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 20 June 2018, at 15:00 CET.  Latest press releases from BioGaia2018-05-23 Management changes at BioGaia2018-05-22 BioGaia signs exclusive agreement in Mongolia 2018-04-26 General Meeting of BioGaia

Pomegranate InvestmentAB (publ) Releases Financial Report for the first four months of 2018 and the period January 1, 2017–April 30, 2018.

Highlight of the reporting period At the Company's AGM on May 15, 2017 the shareholders approved to change Pomegranate's financial year to 1 May – 30 April, to be more synchronised with the reporting of portfolio companies, and as a result the current financial year was extended to sixteen months (January 1,  2017 – April 30, 2018) to enable the transition. The comparisons to the result of financial year January 1, 2017 – April 30, 2018 and the 4-month period January 1, 2018 – April 30, 2018 has been made with the previous financial year results of 2016 full year and first quarter of 2017.  · Net result for the period January 1, 2017 – April 30, 2018 was EUR -29.2 million (mln) (January 1, 2016–December 31, 2016: EUR 35.2 mln). Earnings per share were EUR -5.8 (9.8).  · Net result for the 4-month period January 1, 2018 – April 30, 2018 was EUR  -25.4 million (Q1 2017: EUR -1.8 mln). · The net asset value of the Company was EUR 131.4 mln on April 30, 2018, (March 31, 2017: 158.9), corresponding to EUR 24.3 per share, (March 31, 2017: 29.4).  · The Company’s net asset value per share in EUR decreased by 24% over the period January 1, 2017– April 30, 2018. The Company’s net asset value per share in EUR decreased by 16% over the period January 1, 2018– April 30, 2018. Pomegranate has performed a broad risk adjusted valuation update of all recent transaction valuations in portfolio companies. · In February 2018, Pomegranate committed to invest EUR 12.7 million in Sarava’s funding round, out of which EUR 8.9 million had already been transferred as per April 30, 2018 and another EUR 3.8 is committed through signed Memorandum of Investment (“MOI”). After the transaction Pomegranate’s stake in Sarava amounts to 15.7% as per April 30, 2018. The MOI signed on February 28, 2018 marked the result of negotiations which had been ongoing from autumn 2017.  · In April 2018, Pomegranate together with the founders and other shareholder in Carvanro decided to discontinue the project, due to insufficient traction of the company’s product in the market, relative to the expected future funding need to continue the project. As per April 30, 2018 the Pomegranate has recognised a full write-off of the previous company value of EUR 1.4 million. · Cash and cash equivalents amounted to EUR 23.4 million as per April 30, 2018 (December 31, 2016: 29.0). Additionally, the Company had short term investments with Griffon Capital at a value of ca EUR 2.6 million as per April 30, 2018. Which means a total sum of cash and short term investments of EUR 26.0 million.  · The number of outstanding shares at the end of the period was 5,404,601.  Events after the end of the reporting period · The Company has given notice of exercise of the first tranche of Sheypoor stock options held by Pomegranate as per May 31, 2018. In accordance with the option agreement, the options to be exercised correspond to 3.03% in the capital Sheypoor for the total consideration of EUR 534,688.This exercise provides Sheypoor with some extra immediate funding to continue marketing and other initiatives at a favourable valuation for Pomegranate Management Comments Florian Hellmich, CEO of Pomegranate Investment AB (publ), commented:   “We recognise the challenging environment post the US unilateral withdrawal from the JCPOA and the need to maintain utmost flexibility to deal with a lot of moving parts. As a consequence we have made prudent risk-adjustments to our NAV. We are confident that together with our local partners and portfolio companies we are well equipped to deal with these challenges. Our healthy cash balance is an integral part of allowing us to continue successfully executing our strategy as evident by how a number of our portfolio companies are continuing to thrive– in itself represent important data points of companies that contribute to a resilient economy.“ For additional information, please visit the Company’s website at www.pomegranateinvestment.comor contact: Investor Relations contact: Gustav Wetterling, CFOTel: +46 8 545 015 50Email: ir@pomegranateinvestment.com About Pomegranate  Pomegranate Investment AB (publ) is based in Sweden and was founded in 2014 by a pioneering team with a long and successful track record of investing in high growth companies in emerging markets, particularly in the technology sector. Pomegranate is an investment company that has a strong position primarily in Iran’s consumer technology sector, which, with the easing of international sanctions, represents an extraordinary growth opportunity for European investors. We are entrepreneurs, we have invested in entrepreneurs and a significant proportion of our investors are entrepreneurs themselves.  This press release does not constitute an offer of any securities of Pomegranate Investment. This press release may not be distributed in the United States or to any “U.S. person”, including any U.S. citizen or permanent resident (‘green card holder’) or any entity organised in the United States, whether located inside or outside the United States. Pomegranate shares represent an investment in Iran that is not suitable for U.S. persons.

Nuevolution publishes prospectus in connection with the listing on Nasdaq Stockholm

Stockholm, 20 June 2018, Nuevolution AB (publ) (“Nuevolution” or the “Company”) announced that Nasdaq Stockholm’s listing committee had approved that the Company’s shares are admitted to trading on Nasdaq Stockholm’s main market. The prospectus that has been prepared in connection with the listing was approved and registered by the Swedish Financial Supervisory Authority today on 20 June 2018 and is now available on Nuevolution’s website, www.nuevolution.com.  The first day of trading on Nasdaq Stockholm occurs on 25 June 2018. Last day of trading on Nasdaq First North Premier is 21 June 2018. The ticker for the Company’s shares, NUE, will remain unchanged. The ISIN code for the Company’s shares, SE0007730650, will also remain unchanged. Shareholders in the Company do not need to take any action in connection with the list change. For further information, please contact: Alex Haahr Gouliaev, CEOPhone: +45 7020 0987       E-mail: ahg@nuevolution.com   Henrik D. Simonsen, CFO  Phone: +45 3913 0947       E-mail: hs@nuevolution.com            The information was sent for publication, through the agency of the contact persons set out above, on 17.00 CET on 20 June 2018. About Nuevolution AB (publ) Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology. Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com.

New RayStation 8A release adds support for TomoDirect Treatment Delivery

The release of RayStation 8A is one more step towards RaySearch’s goal of unifying treatment planning for as many treatment delivery systems as possible, eliminating the complications and additional steps that arise from using multiple software systems. All TomoTherapy and Radixact users now have access to advanced RayStation features, including multi-criteria optimization (MCO), adaptive planning and Plan Explorer. With the addition of Plan Explorer functionality, TomoTherapy and Radixact clinics can now automatically generate a large number of treatment plans for defined clinical goals and combinations of treatment techniques and machines, optimizing the use of treatment machines and increasing treatment planning efficiency. Improvements for proton and carbon ion therapy include automatic selection of range shifter for PBS machines and DICOM export of magnets in the lateral spreading device sequence for all ion treatment machines. Ion beam commissioning tools have also been refined for easier use, and carbon ion treatment machines are now supported in RayStation’s physics module. RayStation 8A strengthens integration with RayCare. Other general improvements include the possibility to choose independent isocenters and/or independent directions for robust optimization, the ability to view DVHs in absolute volume and an improved user interface for DICOM import. Johan Löf, CEO of RaySearch, says: “This latest RayStation release is an important step forward. We are very pleased to expand our support for the TomoTherapy platform, giving all users access to innovative RayStation features. We have also included some significant additional features for particle therapy, which is an important focus area for RaySearch. Many more exciting developments are in the pipeline for upcoming releases, and we will announce these in the near future.” About RayCare RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy. About RayStation RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability. About RaySearch RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. To learn more about RaySearch, go to: www.raysearchlabs.com  * Subject to regulatory clearance in some markets. For further information, please contact: Johan Löf, President and CEO, RaySearch Laboratories AB (publ) Telephone: +46 (0)8-510 530 00 johan.lof@raysearchlabs.com 

Asetek to Feature Latest Intel® Compute Modules at ISC18

June 21, 2018 – Asetek, a leader in providing flexible liquid cooling solutions for HPC and Data Centers, will be showing its latest liquid cooling technology integrated in Intel® Compute Modules at the International Supercomputing Conference (ISC18) in Frankfurt, Germany, June 25–27, 2018.The release of these new liquid cooled compute modules from Intel is a direct result of the ongoing collaboration between Intel and Asetek announced in March 2018. Intel® Compute Modules  featuring both Intel® Xeon® Scalable Processors and Intel® Xeon Phi™ Processors will be on display at booth #H-722.  “Asetek is excited with this next step in the ongoing collaboration with Intel,” said John Hamill, Asetek Chief Operating Officer. “The integration of Asetek liquid cooling technology in Intel® Compute Modules HNS2600BPBLC and HNS7200APRL serves as further validation of low pressure distributed liquid cooling for HPC and Data Center sites.”Both Intel® Server Board S2600BP-based and Intel® Server Board S7200APR- based Data Center Blocks have been validated with Asetek technology for HPC and Data Center environments.The Intel® Compute Module HNS2600BPBLC features Intel® Xeon Scalable Processors with Asetek Direct-to-Chip (D2C) liquid-cooling.  This product is targeted for liquid cooled data centers and utilizes Asetek’s RackCDU to transfer the heat captured from the compute modules to facilities liquid. This allows data center operators to realize increases in rack density and reduction in data center cooling costs.The Intel® Compute Module HNS7200APRL features Intel® Xeon® PhiTM Processors with Liquid to Air Assisted (LAAC) technology, allowing the heat captured by the liquid to be expelled by traditional data center air handling.  This allows the use of higher performance processors in dense configurations, without any changes to the data center infrastructure.“Our customers want to use the high-performance Intel processors, and often in very dense configurations,” said Mike Kendrick, HPC Segment Lead, Intel Data Center Solutions Group. “These solutions are examples of how we can provide users the choice of using liquid to boost performance in existing air-cooled data centers or to maximize performance and density in liquid cooled data centers.”To learn more about Asetek liquid cooling, please visit www.asetek.com .About AsetekAsetek is the global leader in liquid cooling solutions for data centers, servers and PCs. Founded in 2000, Asetek is headquartered in Denmark and has operations in California, Texas, China and Taiwan. Asetek is listed on the Oslo Stock Exchange (ASETEK). For more information, visit www.asetek.comMedia Contact:Larry VertalData Center Marketing+1-408-256-3118lve@asetek.com

Capio appoints Attila Vegh as new CEO

"I am pleased to announce the appointment of Attila Vegh as the new CEO for Capio. He will bring a wide range of experience combined with a dedication to manage change and transformation in clinical environments, both in the private and the public sector", says Michael Wolf, Chairman of the Board of Capio AB. "I also want to take the opportunity to express my and the Boards gratitude to Thomas Berglund who has served Capio for the last ten years. Under his leadership Capio has established itself as market leader through the strategies of Modern Medicine, Rapid Recovery and Modern Management ", continues Michael Wolf. Attila Vegh is a trained doctor with a proven track record as a CEO. He's aged 42 and is currently CEO of Penta Hospitals International, a multi-national healthcare group with over 70 hospitals and clinics in three countries, employing over 14,000 staff. Previous positions include CEO of University Hospitals of South Manchester and CEO at Cambridgeshire and Peterborough Foundation Trust in the United Kingdom. Prior to his CEO roles, Attila Vegh spent five years at McKinsey & Company, leading the transformation programs of large hospital groups across Europe, US and Asia. In addition to his medical training, he also holds a Ph.D in Molecular Cancer Research from the University of Paris and an MSc in Health Management from Imperial College London."I am looking forward to joining Capio, which has a strong international reputation. Healthcare markets are transforming and with Capios strong medical knowledge and operational capabilities, I see exciting potential for its future development. Together with the management team, I look forward to further advancing the company by accelerating the execution of the Capio strategy, with a strong focus on specialization and digitalization", says Attila Vegh. "With the appointment of Attila Vegh we secure a strong and proven manager for Capio and we will now accelerate our strategy to drive medical quality, growth and shareholder value. To ensure this development, the Board and management continuously review operational and structural measures on the back of our increased focus on specialization and digitalization” ends Michael Wolf. For information, please contact:Michael Wolf, Chairman of the Board, Capio ABTelephone: +46 761 11 34 14 This is information that Capio AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 (CET) on June 21, 2018. Capio AB (publ) is a leading, pan-European healthcare provider offering a broad range of high quality medical, surgical and psychiatric healthcare services through its hospitals, specialist clinics and primary care units. Capio operates in five countries; Sweden, Norway, Denmark, France and Germany. In 2017, Capio’s 13,314 employees (average full-time equivalents) provided healthcare services during 5.1 million patient visits across the Group’s facilities, generating net sales of MSEK 15,327. Capio operates across three geographic segments: Nordic (57% of Group net sales 2017), France (35% of Group net sales 2017) and Germany (8% of Group net sales 2017). For more information about Capio, please see www.capio.com.

Alligator Bioscience’s ATOR-1017 strongly activates both T cells and NK cells, important for the effective eradication of tumor cells

Lund, Sweden, June 21, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, will present additional preclinical data for the drug candidate ATOR-1017 at the 3rd Annual World Preclinical Congress in Boston, US. ATOR-1017 is a monoclonal antibody being developed for the treatment of metastasizing cancer. ATOR-1017 activates the costimulatory receptor 4-1BB which is highly expressed on both T cells and NK cells in the tumor environment. These new data show that ATOR-1017 activates NK cells as well as T cells, both contributing to an effective immune-mediated killing of tumor cells. NK cells are immune cells that directly target tumor cells which attempt to evade the immune system. NK cells also enhance the cytotoxic response induced by tumor specific T cells. Agonistic antibodies recognizing 4-1BB will therefore strengthen the tumor killing capacity of both NK cells and cytotoxic T cells. The data further support a best-in-class profile for ATOR-1017, with demonstrated high efficacy and potential for tumor-directed immune activation. “These preclinical data provide further evidence of ATOR-1017’s unique positioning as a best-in-class 4-1BB antibody. ATOR-1017 has the properties and potential to minimize side-effects and to induce a powerful, long lasting immune response,” said Christina Furebring, SVP Research, at Alligator Bioscience. Dr Karin Enell Smith, Senior Scientist Preclinical Development at Alligator, will give an oral presentation with the title: “ATOR-1017 – A tumor directed Fcγ-receptor cross-linking dependent 4-1BB agonistic antibody” today at 3:30 p.m. EDT (9:30 p.m. CEST) For further information, please contact:Cecilia Hofvander, Director Investor Relations & CommunicationsPhone +46 46 286 44 95E-mail: cecilia.hofvander@alligatorbioscience.com The information was submitted for publication, through the agency of the contact person set out above, at 8:00 a.m. CEST on June 21, 2018. About ATOR-1017ATOR-1017 is an immunostimulatory antibody (IgG4) that binds to the costimulatory receptor 4-1BB (also known as CD137) expressed on tumor-specific T cells and NK cells. 4-1BB has the capacity to support the immune cells involved in tumor control, making 4-1BB a particularly attractive target for cancer immunotherapy. ATOR-1017 is differentiated from other 4-1BB antibodies, partly because of its unique binding profile, but also because its immunostimulatory function is dependent on cross-linking to Fc-gamma receptors on immune cells. The aim is to achieve effective tumor-targeted immune stimulation with minimum side effects. About Alligator BioscienceAlligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes four lead clinical and preclinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit www.alligatorbioscience.com .

SciBase releases major improvements to Nevisense

"To be accepted by an even broader customer group, we needed to improve the ease of use of Nevisense and make it easier to integrate into a clinic’s workflow. We have achieved this with Nevisense 3.0 and I am delighted to announce the release of the product. Not only does the upgrade dramatically simplify the testing process, it also delivers an improved level of clinical accuracy. We consider this the most important update in the history of the product, and believe this will allow us to address the needs of the mainstream market.” says SciBase CEO Simon Grant. The key improvement is the elimination of the need for a reference measurement, which up until now has been the most complex part of the Nevisense test. Removing this streamlines the measurement procedure and makes Nevisense straightforward to learn and use. This is a very important improvement in usability and makes the product much easier to integrate into the patient flow at dermatology clinics. At the same time the new algorithm has been shown to provide an improved level of clinical accuracy. Sensitivity has remained very high and increased slightly to 97%. Specificity has increased to 38% and negative predictive value (NPV) has improved to 99%. The Nevisense 3.0 upgrade will be installed at a core group of 25 users in the EU (primarily Germany) in June, and will be available for general release after the summer. “We realise the impact that the launch of the new product may have on new customers who will prefer to wait for the general release to purchase Nevisense. We expect this to have a temporary negative effect on sales, balanced by an expected increase in incoming orders”, says Simon Grant. For more information, please contact:Simon Grant, CEO SciBaseTel: +46 72 887 43 99Email: simon.grant@scibase.com   This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on June 21, 2018. About SciBase and Nevisense SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com.

QuickCool AB enters into a financing agreement with European High Growth Opportunities Securitization Fund through its advisor Alpha Blue Ocean

QuickCool has entered into the financing agreement in order to secure the Company's financing. The financing will provide capital to QuickCool over the next 18 months and finance the finalization of the Company’s CE-mark activities, as well as the production start and market launch. The annual general meeting on 3 May 2018 and the extraordinary general meeting on 4 June 2018 empowered the Board of Directors to issue convertibles and warrants. These authorizations have enabled this financing agreement. “We have investigated and evaluated several cost-effective and flexible financing alternatives. This financing solution fits our short-term needs for ordering components, for finalizing our CE-mark process and related activities as well as the initial market launches. Now, we can focus on our launch without losing momentum", says QuickCool’s CEO Fredrik Radencrantz.Pierre Vannineuse, CEO and founder of London based Alpha Blue Ocean Investment Group, and who also heads European High Growth Opportunities Securitization Fund, comments: "We welcome QuickCool to our portfolio of investments. This transaction is part of Alpha Blue Ocean's intention to invest two Billion Euros in European healthcare companies in the next few 24 months. QuickCool’s patented intranasal cooling solution is unique and the Company is in a very exciting phase, so we are really looking forward to following QuickCool’s expansion at close range." Main conditionsThe financing solution is based on the issuance of convertible bonds and warrants with the right to convert or to exercise these into class B shares of the Company. The financing shall take place over a 18 month period. During this period, the Company will be able to receive SEK 14 Million through the issuance of seven tranches comprising convertible bonds with warrants attached. If the Company decides to increase the funding, the Company will be able to receive an additional SEK 12 Million through the issuance of up to six additional tranches. The tranches amount to SEK 2 Million each. European High Growth Opportunities Securitization Fund also entered into a share lending agreement for a total number of 629,000 shares with one shareholder of the Company. In connection with each Tranche, warrants will be issued entitling European High Growth Opportunities Securitization Fund to receive class B shares of the Company upon their exercise. If all warrants issued under the total commitment are exercised, the Company will receive SEK 7.8 Million (i.e. 30 per cent of the total commitment). All in all, this means that the Company may receive up to SEK 33.8 Million. Convertible bonds must be converted into class B shares within 12 months from their respective date of issuance. Warrants must be exercised within 3 years from their respective date of issuance. Convertible bonds will be issued at a subscription price corresponding to their nominal value. The convertible bonds will have to be converted within twelve months as from their respective issuance date and at a conversion price corresponding to 90% of the lowest daily VWAP (volume weighted average price) during the 15 trading days prior to the receipt of a conversion request. The exercise price of the warrants will be calculated, for each Tranche of warrants, as 120% of the lowest daily VWAP observed during the 15 trading days prior to the trading day on which the Company requests European High Growth Opportunities Securitization Fund to subscribe for new convertible bonds, that is when the Company calls for a Tranche. However, it is specified that regarding the first tranche, the exercise price of the warrants shall be equal to 120% of the lower between SEK 1.7030 and the lowest daily VWAP over the 15 trading days prior to the request to issue the first tranche. If the total commitment is exercised, which means convertible bonds of SEK 26 Million in total nominal value, the costs of the Company for, among other things, financial and legal services will amount to approximately 7 per cent of the overall commitment. In the event that all warrants are exercised, the costs are estimated to be just over 5 percent of the total commitment. About European High Growth Opportunities Securitization Fund (EHGO)European High Growth Opportunities Securitization Fund SF is an institutional investment company based in Luxembourg which focuses on financing innovative companies in Europe that are deemed to be significantly undervalued. Alpha Blue Ocean is the exclusive advisor to EHGO. Their mandate is to invest in innovative European companies, thereby supporting their needs for growth capital by providing a credible European funding option. About Alpha Blue Ocean Investment Group Alpha Blue Ocean, founded by Pierre Vannineuse, is responsible for a family of investments and operates across multiple jurisdictions and focuses on financing innovative technologies while retaining a passive role in the management of its portfolio companies. Alpha Blue Ocean specialises in providing flexible and innovative nonInvasive Loans and Equity-financing to listed companies globally and in health, energy, mining and technology. Alpha Blue Ocean's head office is based in London, United Kingdom. For more information, please contactFredrik Radencrantz, CEOPhone: 046-286 38 40E-mail: fredrik.radencrantz@quickcool.se This information is such that QuickCool AB is required to make public in accordance with the EU’s market abuse regulation (MAR) and the Swedish Securities Market Act. The information was made publicly available by the Company’s contact person on 20 June 2018. Quickcool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the Quickcool SYSTEM. Quickcool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. Quickcool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to www.quickcool.se.

BONESUPPORT provides update on US orders of CERAMENT BVF

Lund, Sweden, 08:30 CET, 21 June 2018 – BONESUPPORT™ an emerging leader in Orthobiologics for the management of bone voids, today provides an update on the US orders of CERAMENT BVF. Following BONESUPPORT’s decision to set up its own distribution network in the US and terminate its current exclusive distribution agreement, as announced 17 May 2018, its current distributor, Zimmer Biomet, has cancelled the majority of its orders for a 3-month period starting in June. In-market sales of CERAMENT BVF in the US are continuing to show good growth with this increasing demand being met from Zimmer Biomet’s current inventory and the inventory of its distributor network. “Today’s announcement highlights the importance of BONESUPPORT taking control of its commercial platform in the US. The evaluation of potential distribution partners is progressing to plan. We expect to have a strong coverage of the US market in place in late October, positioning us to create more direct and stronger relationships with our US customer base. This enhanced commercial platform will allow us to successfully market our highly differentiated products, particularly CERAMENT G, which we aim to launch in the US market in 2021”, said Emil Billbäck, CEO of BONESUPPORT. Zimmer Biomet retains the right to sell and distribute CERAMENT BVF on an exclusive basis until 20 October 2018, and on a non-exclusive basis until 20 April 2019. This information is such information as BONESUPPORT HOLDING AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30am CET on 21 June 2018. 

Preem and Setra Collaborate on Renewable Fuel

Petter Holland, CEO Preem, and Hannele Arvonen, CEO Setra Group. Photo: Sten Jansin.The planned production facility will turn sawdust into pyrolysis oil, a renewable raw material for biofuel. Construction is expected to begin in 2019, and the facility is estimated to provide around 25,000 tonnes of pyrolysis oil per year that, via Preem’s refinery in Lysekil, will be refined into biofuel. An application for an environmental permit has been made. “This is Europe’s first production facility for pyrolysis oil linked to a refinery. To meet Sweden’s national target of 70 percent fewer carbon emissions in the transport sector by 2030, a number of measures are required. This is why we were immediately interested when Setra got in touch with their plans for a pyrolysis oil manufacturing facility. It’s important to invest in different biofuels, with sawdust being one possibility,” says Sören Eriksson, development engineer at Preem. “Sawdust is a by-product in our manufacture of wood products, and the possibility of producing pyrolysis oil, which can then be used in biofuel, is completely in line with Setra’s strategy to increase the value and climate benefit of our products. We’ve been running the pyrolysis oil manufacturing project with the aim of finding a partner for commercial applications. The fact that Preem now wishes to invest in this facility with us is extremely positive,” says Hannele Arvonen, CEO of Setra Group. The partnership with Setra is part of Preem’s ambition to manufacture 3,000,000 cubic metres of renewable fuel at refineries in Lysekil and Gothenburg by 2030. In 2017 a total of around 9,000,000 cubic metres of fuel were sold in Sweden, of which just over 1,900,000 were biofuel, according to Svenska Petroleum och Biodrivmedel Institutet (SPBI, the Swedish petroleum and biofuel institute). Around 15 percent of all biofuel was produced in Sweden, with the rest being imported from other countries. FACTS – PyrolysisPyrolysis is a process in which a substance is rapidly heated to a high temperature so that the solid material is vaporised and can be condensed into a liquid. Through pyrolysis, branches, roots, tops and sawdust can be turned into oil, which can then be refined into renewable petrol and diesel. For further information, please contact:Preem’s press telephone, +46 (0)70 450 10 01, press@preem.seHannele Arvonen, CEO Setra Group, +46 (0)70 618 19 17Pontus Friberg, Director Enterprise Risk Management Setra Group, +46 (0)70 234 18 94Sören Eriksson, development engineer Preem, +46 (0)70 450 11 05Niclas Brantingson, press officer Preem, +46 (0)70 362 03 99  About PreemPreem is the largest fuel company in Sweden. Our vision is to lead the transformation towards a sustainable society. Our two refineries are among the most modern and environmentally adapted in Europe, with a refining capacity of more than 18 million cubic meters of crude oil per year. Our business encompasses production, sales, distribution, trading and goods supply. We refine and sell petrol, diesel, heating oil and renewable fuels to companies and consumers in Sweden and Norway. Around two-thirds of our production is exported. We also have a nationwide service network with some 570 fuel stations for private and commercial traffic. Preem employs around 1,400 people, of which 950 work at the refineries. Preem had a turnover of SEK 69 billion in 2017. Read more at www.preem.com. About SetraSetra is one of Sweden’s largest wood products companies. We process raw material from responsibly managed forests and offer climate-friendly products and solutions for building and living in a global market. The Group has approximately 800 employees and annual sales of approximately SEK 4 billion. Exports to Europe, North Africa, the Middle East and Asia account for about 65% of sales. Read more at www.setragroup.com.

Mr Green winner at EGR Marketing and Innovation Awards 2018

In an industry, as generic as online casino, standing out through a creative usage of marketing channels is key to attract and retain your customers. The usage of marketing channels in a relevant and efficient way was the key criteria in this year’s challenge set by the EGR jury. Jesper Kärrbrink, CEO Mr Green Ltd, commented; “Every year in December, all casino operators across the industry bring their best game to attract the most players to their sites. A successful Christmas period is not only important to close of the year, it also builds momentum going into the next year. Being recognised for our creativity and ability to entertain in a relevant way did not go unnoticed by our players last year and we are happy to see it also appealed to the EGR jury." Mr Green’s won the award for a Christmas calendar campaign filled with challenges based on the player’s preferences instead of classic bonus offers. In total over 50 tailored challenges where set up to fit every player’s needs. Being the gentleman of online gaming, all challenges followed the UKGC criteria across all markets. “We base all our product development and player communication on data”, Kärrbrink continued. “The individual player interest is a key driver for our actions. Last year’s Christmas calendar was a great test proving relevance is key when delivering true entertainment and we look forward to taking this one step further this year delivering a 1:1 player experience fully tailored for each individual.”

Nightingale Health and UK Biobank announce major initiative to analyse half a million blood samples to facilitate global medical research

Nightingale Health, the Finnish innovator of an internationally recognized blood biomarker technology for studying chronic diseases, will analyse the biomarker profiles of 500,000 blood samples from UK Biobank. The ground-breaking research initiative was announced today at the UK Biobank Scientific Conference 2018 in London.  Nightingale’s biomarker profiling technology will be used to analyse UK Biobank blood samples by measuring metabolic biomarkers that recent studies have found are predictive of future risk for heart disease, type 2 diabetes and many other common chronic diseases. Until recently, technological constraints and prohibitive costs have prevented the analysis of comprehensive metabolic data from large-scale biobank collections, but this process has been made viable by Nightingale’s technology, which measures over 200 metabolic biomarkers in a single blood test. This initiative will further enrich the world’s most detailed public health database provided by the UK Biobank.  Professor Sir Rory Collins, UK Biobank’s Principal Investigator, said the commitment by Nightingale to perform these assays would allow researchers around the world to advance health research more quickly. He expects the combination of these biomarker data with the detailed health information that participants have already provided to generate many new insights. “We are delighted to see these novel blood sample analyses being done in UK Biobank,” said Professor Collins. “We already have an enormous amount of information about the lifestyles and genetic make-up of the participants in UK Biobank, as well as about their health, and are currently conducting imaging studies of their brains, hearts and bodies. Providing the medical research community with these additional high quality metabolic biomarker data on such a large scale will enhance discovery science and population science, providing opportunities to benefit patient care and public health.” “Analysing 500,000 blood samples from a single study with Nightingale’s comprehensive biomarker profiling technology allows us to uncover metabolic signatures that reflect a risk for future disease onset, as well as their underlying risk factors. We anticipate this detailed molecular readout of the health state, combining both lifestyle and genetic makeup, will result in a wealth of scientific applications from the research community. This will be relevant not only to the British population but also yield ground-breaking science and enhanced drug development opportunities with a global public health impact,” said Dr. Peter Würtz, Scientific Director and Founder, Nightingale Health. Nightingale Health’s technology has been previously used to analyse more than 500,000 blood samples from over 200 cohort studies and clinical trials around the globe, with more than 150 peer-reviewed publications showcasing how the detailed metabolic biomarker data provide novel insights into health and disease. “Nightingale’s mission is strongly linked to scientific evidence generation. This means working with world-leading institutions and biosample collections to continuously improve the understanding of health and disease. Our aim is to translate this understanding into improved early prediction of diabetes and cardiovascular diseases, achieving better healthcare for everyone. Our initiative with the UK Biobank demonstrates Nightingale’s unwavering commitment towards supporting innovative medical science carried out by researchers from across the world,” said Teemu Suna, CEO and Founder, Nightingale Health. The initiative corresponds to over 10 million EUR investment in UK Biobank and will be funded by Nightingale Health, with analyses of UK Biobank samples being performed at Nightingale’s laboratory in Finland. In line with the founding principles of the UK Biobank, this metabolomic data will be incorporated back into the UK Biobank's resource following a 9 months exclusivity period for Nightingale Health and made openly available to the scientific community. 

Erja Yläjärvi appointed Senior Editor-in-Chief of Iltalehti

Alma Media Corporation        Press release                              21 June 2018 ERJA YLÄJÄRVI APPOINTED SENIOR EDITOR-IN-CHIEF OF ILTALEHTI Erja Yläjärvi, 41, M.Soc.Sci, has been appointed Senior Editor-in-Chief of Iltalehti. Yläjärvi currently works as Managing Editor at Helsingin Sanomat. She is responsible for the HS.fi newsdesk and all newsrooms. Yläjärvi has worked for Helsingin Sanomat since 2013, and before the newsdesk she was in charge of editorial teams for areas such as feature and lifestyle. In 2012–2013, Yläjärvi was the Editor-in-Chief of Kouvolan Sanomat. Yläjärvi has also worked as a News Editor and a Brussels EU correspondent for the Finnish News Agency as well as a political journalist for Väli-Suomen Media and a foreign reporter for Keskisuomalainen. Yläjärvi will start work as the Senior Editor-in-Chief on 24 September 2018. She will report to Kari Kivelä, Senior Vice President of the Alma Consumer business unit. -        Erja’s background is an excellent fit for Iltalehti’s content profile, which consists of both news and diverse lifestyle content. Dynamic media needs daring leaders like Erja Yläjärvi. Under the leadership of Erja and Perttu Kauppinen, Editor-in-Chief for News, the Iltalehti editorial office will be prepared to face the future challenges of digital media and to serve its monthly audience of three million even better through several channels, says Kari Kivelä, Senior Vice President of Alma Consumer. -        Iltalehti is, without a doubt, one of the leading digital news brands in Finland. I am very pleased to have the opportunity to be part of developing a media outlet that has such broad reach throughout Finland. I have always been interested in all kinds of news, from politics to sports and lifestyle. That is why the breadth of topics covered by Iltalehti makes this role particularly interesting to me, says Erja Yläjärvi. For more information, please contact: Kari Kivelä, Senior Vice President, Alma Consumer, tel. +358 10 665 2032

Kesko becomes the largest omnichannel player in the Baltics by acquiring 1A Group

Kesko Corporation's joint venture in the Baltics, Kesko Senukai, has agreed to acquire 1A Group, one of the leading online retail market players in the Baltic states, with net sales of approximately €41 million in 2017. The acquisition of 1A Group will make Kesko Senukai one of the leading e-commerce operators in the Baltics with online operations in Estonia, Latvia and Lithuania. The parties do not disclose the transaction price.  Kesko’s strategic objective in the building and technical trade is to strengthen its market position in Northern Europe and improve profitability in all operating countries. By acquiring 1A, Kesko will gain a strong foothold in the Baltic countries’ growing ecommerce market. "The e-commerce market in the Baltics is fast growing and strongly outpacing brick-and-mortar retailing. With this acquisition, we will become the largest omnichannel player in the Baltics and can serve our customers via our comprehensive store network as well as growingly online. 1A complements the existing online sales of Kesko Senukai Digital especially in Latvia and Estonia, providing us a comprehensive e-commerce platform to serve the whole Baltic market,” says Jorma Rauhala, President of Kesko’s building and technical trade division and deputy to Kesko's President and CEO. 1A Group was founded in 2002 and has grown into one of the leading online retail market players in the Baltic states. The company started as an electronics online retailer, but has since transformed into a multi-industry product online retailer. K Group’s building and technical trade division operates in eight countries and growingly online. Kesko Senukai is the leading Do-It-Yourself retail company in the Baltics and operates 22 K-Senukai stores in Lithuania, 9 K-Senukai stores Latvia, 8 K-Rauta stores in Estonia and 17 Oma stores in Belarus as well as a successful e-commerce platform. The completion of the acquisition is subject to the approval of the local competition authorities and the fulfilment of the other terms and conditions of the transaction. The transaction is expected to be completed during the second half of 2018. Further information:Jorma Rauhala, President of the building and technical trade division of Kesko Corporation and Deputy to President and CEO of Kesko Corporation, tel. +358 105 322 211, jorma.rauhala@kesko.fiJessica Diktonius, Vice President, Communications, K Group's building and technical trade, +358 40 709 9176, jessica.diktonius@kesko.fi Kesko Corporation DISTRIBUTIONMain news mediawww.kesko.fi

Xspray Pharma gets go-ahead from the Swedish MPA for clinical study

“We are pleased with the progress of the project and following the decision of the MPA, we can now proceed with our plan for clinical studies,” commented Per Andersson, CEO of Xspray Pharma. The current study is intended to confirm the formulation of the product candidate HyNap-Dasa. The results will form the basis of the following registration studies. The results from the current study are expected to be available by the end of the third quarter. HyNap-Dasa is the first in a portfolio of product candidates that Xspray Pharma is developing with the target to haver products ready to launch on the US market during 2020-2026. All of the product candidates in the portfolio are versions of cancer drugs currently on the market, based on protein kinase inhibitors (PKI) and used for cancer treatments. For further information, please contact: Per Andersson, CEO, Xspray Pharma AB (publ)Mobile: +46 (0)706 88 23 48E-mail: per.andersson@xspray.com About Xspray Pharma              Xspray Pharma AB (publ) is a product development company with several product candidates under clinical development. Xspray uses its innovative RightSize-technology in order to develop improved and generic versions of already marketed cancer drugs, primarily protein kinase inhibitors (PKI), for treating cancer. The segment is the second largest within the oncology department and the drug prices are very high. Through its innovative technology, Xspray can enter the market as first competitor to the original drugs available today without the hindrance of secondary patents. Xspray’s goal is to have up to seven products ready for launch on the American market, with a first product launched at the latest by 2021. The company has patents on production technology, equipment and the resulting products. The shares in Xspray Pharma (publ) are traded on Nasdaq First North Stockholm and Redeye is the Certified Adviser for the company. Xspray Pharma AB (publ) Gunnar Asplunds Allé 32 171 63 Solna www.xspray.com 

Duni launches fully recyclable coffee mug during the Volvo Ocean Race

When the Volvo Ocean Race starts its eleventh and final stretch on 21 June, everyone is invited to a big sailing event in Gothenburg. The competition has become famous for being one of the leading sail racing contests that takes place around the world, but also for its focus on the question of plastic pollution in our oceans. Among other things, different summits are held on this topic at each stop of the race. Duni is an official supplier of the Volvo Ocean Race in Gothenburg for environmentally adapted products and services at the event's restaurants and dining area. During the event, a unique coffee cup will be launched, and it will be the first in Europe of its kind. For the first time, Duni has managed to create a fiber-based takeaway cup of the compostable bagasse, a by-product of sugar cane, and paper pulp. The mug can be used for a variety of drinks, both hot and cold. Bagasse is a material that breaks down quickly and returns to soil within a few weeks in industrial composting. "Developing sustainable products has been one of Duni's top priority areas for several years, and today we offer a wide range of alternatives with high design factor under our ecoecho® brand," said Saloni Deva, IR and Communications Manager at Duni. "In bagasse, we have found an incredibly interesting material that we constantly are investigating and testing to get into upcoming product lines. That we have now found a solution to produce one of the most used products - a takeaway coffee mug - is a success in itself, both for Duni and for the environment." The coffee mug is launched in six sizes, and can be profiled with print. :: For more information, please contact:Saloni Deva, IR and Communications Managerphone +46 734 196389e-mail saloni.deva@duni.com  For more information about the product, please contact:Niklas Bengtsson, Business Area Meal Service, Sales Managerphone +46 734 196147e-mail nicklas.bengtsson@duni.com  :: About the material bagasseBagasse is based on a residual of sugar cane that is created in the process of sugar production. The material goes back to soil in just a few weeks when composted. About ecoecho®Duni has developed an entire range that has been given the name ecoecho®. It includes products made of environmentally conscious materials in order to limit the use of non-renewable raw materials and also reduce the carbon footprint. For inclusion in the ecoecho® range, the material must satisfy the criteria of resource efficiency, renewability, compostability and responsible forestry. :: Press imageshttp://www.mynewsdesk.com/duni/latest_media Links Duni: https://www.duni.com/en/ ecoecho: https://www.duni.com/en/products/ecoecho/  Volvo Ocean Race: http://volvooceanracegoteborg.com 

Nexam Chemical publish newsletter

Read, amongst other things, about the new focus area electronics and the new project, together with Swerea Sicomp and others, regarding the development of high performance resins for the aviation industry, funded by Clean Sky Joint Undertaking. The next issue of the newsletter is planned to be published in September 2018. Note: This news has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version. For further information please contact: Anders Spetz, CEO, +46-703 47 97 00, anders.spetz@nexamchemical.com  ____________________________________________________________________________ About Nexam Chemical Nexam Chemical develops technology and products that make it possible to significantly improve the production process and properties of most types of plastics in a cost-effective manner and with retained production technology. The improved properties include strength, toughness, temperature and chemical resistance as well as service life. The improvements in properties that can be achieved by using Nexam Chemical's technology make it possible to replace metals and other heavier or more expensive materials with plastics in a number of applications. In applications where plastic is already used, Nexam Chemicals products can improve the manufacturing process, reducing material use and enable more environmental friendly alternatives. Example of commercial applications: pipe manufacturing, foam production and high-performance plastics. More information about the business will be found on www.nexamchemical.com. The company´s Certified Adviser is FNCA Sweden AB.

Evolution double victory at EGR B2B Awards winning Live Casino Supplier of the Year for ninth successive year, and Multi-Channel Supplier of the Year

Evolution beat eight other shortlisted suppliers to win the Live Casino Supplier top spot, and 11 others to win the Multi-Channel Supplier award for the first time. In a remarkable unbroken run of nine wins, Evolution Gaming has retained the Live Casino Supplier of the Year award in every single year since the EGR B2B Awards began in 2010. Speaking after the awards ceremony, Martin Carlesund, Evolution Group CEO said: “These last 12 months have seen Evolution once again push the boundaries, working tirelessly to extend our position as the number one Live Casino supplier in an increasingly competitive market.” Carlesund continued: “New Evolution games launched in this past year have included our ground-breaking Lightning Roulette, which was an immediate commercial success for our operators, Texas Hold’em Bonus Poker, including a dedicated ‘First Five’ Progressive Jackpot, and our first ever on-premise Dual Play Baccarat table, at the Grosvenor Victoria Casino in London. We also launched our Salon Privé, the world’s best and most flexible online VIP environment, and extended choice for all types of Baccarat players with the launch of No Commission Baccarat and Dragon Tiger. We also opened our first North American studio, in Vancouver, Canada, and our third major central Live Casino studio in Europe, in Tbilisi, Georgia” Responding to Evolution being named top Multi-Channel Supplier, Carlesund, said: “We are so delighted, not least because this is a really tough category in which we were up against 11 other shortlisted suppliers. “The focus of Evolution’s Multi-Channel submission was our bespoke Dual Play convergence solution, which allows on-premise and online players to play at the same land-based table. Having established market leadership initially with Evolution Dual Play Roulette, this year we launched our first ever Dual Play Baccarat table. “Evolution Dual Play is now clearly the convergence solution of choice for the world’s top land-based casinos — our Dual Play tables are performing exceptionally well on the gaming floors of venues such as London’s Hippodrome Casino, the Grosvenor Victoria, and at the Genting International Casino, Resorts World Birmingham and Genting Manchester to name but a few.” About the EGR B2B AwardsThe annual EGR B2B Awards, which began in 2010, reward and celebrate the very best service providers in the online gaming industry. The awards recognise the achievements of suppliers from all major egaming disciplines including betting and gaming software, networks, mobile, payments, recruitment, IT and infrastructure. The awards event is attended by over 500 egaming supplier and service provider professionals.

European Commission backs Minesto roadmap for commercial breakthrough

“This grant underscores Minesto’s ability and industry-leading track record in obtaining public funding support from the EU”, said Dr Martin Edlund, CEO of Minesto. “More importantly, it also shows that the European Commission acknowledges and supports our market entry approach based on initial small-scale installations and early-stage customer involvement.” Supported by potential customers and partners in the Faroe Islands, France and Belgium, Minesto’s proposal was one of the few selected by the European Commission in competition with 2,148 other applications from small and medium-sized enterprises (SME) in 43 countries. The awarded phase 1 grant of €50,000 will be used for a feasibility study of commercial Island Mode (off grid) installations of Minesto’s marine energy converter DG100. In addition to composing a commercial product that will enable faster market entry and volume scale-up, the DG100 system also serves a key role in the commercialisation and industrial rollout of Minesto’s utility scale systems, which target the company’s main market of large-scale array installations. SME Instrument is part of the European Commission’s research and development programme Horizon 2020 and supports ground-breaking innovative ideas for products, services or processes that are ready to conquer global markets. Highly innovative small and medium-sized enterprises with a clear commercial ambition and a potential for high growth and internationalisation are the prime target. The SME Instrument is divided in different phases with €50,000 grants for feasibility assessment purposes available in phase 1. In phase 2, grants in the range of €500,000–€2.5m or more are available for innovation development and demonstration purposes. “We are looking forward to compete for the SME Instrument phase 2 together with utility customers”, said Dr Martin Edlund. For additional information please contact: Magnus MatssonCommunications Manager, Minesto AB+46 70 570 75 08press@minesto.com The information in this press release is such that Minesto AB (publ) shall announce publicly according to the EU Regulation No 596/2014 on market abuse (MAR). The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CET on 21 June 2018. About Minesto Minesto is a marine energy technology company with the mission to minimise the global carbon footprint of the energy industry by enabling commercial power production from the ocean. Minesto’s award winning and patented product, Deep Green, is the only verified marine power plant that operates cost efficiently in areas with low-flow tidal streams and ocean currents. In May 2015, Minesto secured a €13m investment from the European Regional Development Fund through the Welsh European Funding Office, for the commercial rollout of Deep Green. Minesto was founded in 2007 and has operations in Sweden, Wales, Northern Ireland and Taiwan. The major shareholders in Minesto are BGA Invest and Midroc New Technology. The Minesto share (MINEST) is traded on the Nasdaq First North Stockholm stock exchange, with G&W Fondkommission as Certified Adviser. Read more about Minesto at www.minesto.com Press images and other media material is available for download via bit.ly/minestomedia. 

Nordic Nanovector Announces First Patient Dosed in Pivotal PARADIGME Trial of Betalutin® in Third-line Follicular Lymphoma Patients

Oslo, Norway, 21 June 2018 Nordic Nanovector ASA (OSE: NANO) announces that the first patient has been dosed in its pivotal PARADIGME Phase 2b trial with Betalutin® (177Lu-satetraxetan-lilotomab) in third-line (3L) follicular lymphoma (FL) patients who are refractory to anti-CD20 immunotherapy (including rituximab), a population with high unmet medical need. PARADIGME is a global randomised Phase 2b clinical trial comparing two Betalutin® dosing regimens (15MBq/kg Betalutin® following 40mg lilotomab pre-dosing; 20MBq/kg Betalutin® following 100mg/m2 lilotomab pre-dosing) in 3L FL patients. PARADIGME aims to enrol 130 patients across 80-85 sites in approximately 20 countries. The objective of PARADIGME is to determine the best dosing regimen for Betalutin® as a new treatment option for 3L FL patients. The data from this study are expected to support market authorisation applications for Betalutin® as a new treatment option for 3L FL patients. The primary endpoint for the trial is overall response rate (ORR) and secondary endpoints include duration of response (DoR), progression free survival (PFS), overall survival (OS), safety and quality of life. Initial efficacy and safety data read-out for PARADIGME is target for the first half 2020. Lisa Rojkjaer MD, Nordic Nanovector CMO, commented: “Dosing of the first patient in PARADIGME marks important progress for Nordic Nanovector in the development of Betalutin® for the treatment of FL patients. We remain convinced of the drug’s potential in this indication following promising clinical data to-date and look forward to advancing this clinical trial to a successful conclusion.” -End- For further information, please contact: IR enquiries Malene Brondberg, VP Investor Relations and Corporate Communications Cell: +44 7561 431 762 Email: ir@nordicnanovector.com International Media Enquiries Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson) Tel: +44 207 638 9571 Email: nordicnanovector@citigatedewerogerson.com About Betalutin® Betalutin® is a tumour-seeking anti-CD37 antibody (lilotumab) conjugated to a low-intensity radionuclide (lutetium-177). CD37 is highly expressed in B-cell non-Hodgkin's lymphoma (NHL), representing a novel therapeutic target. Betalutin® is internalised in tumour cells and prolonged exposure of the nucleus to radiation destroys DNA leading to tumour cell death. Betalutin® also has a crossfire effect limited to a radius of 40 cells, which destroys surrounding tumour cells. Betalutin has shown promising efficacy and tolerability in the Phase 1/2a LYMRIT 37-01 clinical study in relapsed/refractory follicular lymphoma (R/R FL) and is currently in a pivotal Phase 2b trial, PARADIGME, in third line (3L) FL patients who are refractory to standard-of-care anti-CD20-based therapy (including rituximab). About Nordic Nanovector Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.   Further information about the Company can be found at www.nordicnanovector.com

QuickCool AB (publ): QUICKCOOL AB REQUESTS THE FIRST TRANCHE OF CONVERTIBLE LOAN FROM EUROPEAN HIGH GROWTH OPPORTUNITIES SECURITIZATION FUND

Convertible Instruments The board has resolved, based on the general meeting’s authorization, to request the issuance of the first tranche of convertible loan amounting to SEK 2 million by issuing convertible instruments. The convertible instruments can be converted into class B shares of QuickCool. European High Growth Opportunities Securitization Fund has the sole right to subscribe for the convertible instruments by cash payment. The convertible instruments are issued at a subscription price equal to one hundred percent of their aggregate nominal value. The convertible bonds carry no interest and have a maturity of 12 months as from their registration with the Swedish Companies Registration Office, if not converted prior to that date. The conversion price per new share shall correspond to 90 per cent of the lowest daily VWAP according to Spotlight Stock Market/AktieTorget’s market official price list for the class B shares in QuickCool during the fifteen (15) trading days preceding the conversion date. Warrants The board has further resolved, based on the general meeting’s authorization and with deviation from the shareholders’ pre-emptive rights, to issue 500.000 warrants attached to the convertible instruments. Each warrant entitles European High Growth Opportunities Securitization Fund to subscribe for one new class B share in QuickCool, during three years as from their date of registration with the Swedish Companies Registration Office, at an exercise price of SEK 1,20 per share.The warrants are issued free of charge. Upon full exercise of the warrants, QuickCool will be provided with up to SEK 600,000, corresponding to 30 percent of the nominal amount of the convertible bond loan. The terms and conditions for the warrants include customary provisions on recalculation of the exercise price in connection with rights issues etc. The board’s issue resolutions have been made based on the authorization from the annual shareholders’ meeting on 3 May 2018 and the extraordinary shareholders’ meeting on 4 June 2018. For more information, please contact:Fredrik Radencrantz, VDPhone: +4646-286 38 40E-post: fredrik.radencrantz@quickcool.se This information is such that QuickCool AB is required to make public in accordance with the EU’s market abuse regulation (MAR) and the Swedish Securities Market Act. The information was made publicly available by the Company’s contact person on 21 June, 2018. Quickcool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the Quickcool SYSTEM. Quickcool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. Quickcool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to www.quickcool.se

Publication of a Prospectus

  22 June 2018 07:00 BST Publication of Prospectus Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the UK Listing Authority and is available for viewing:  Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme (the "Prospectus").  The last drawdown under the EMTN programme was in 2016.  To view the full document, please paste the following URL into the address bar of your browser.  http://www.rns-pdf.londonstockexchange.com/rns/2100S_1-2018-6-21.pdf A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:  http://www.morningstar.co.uk/uk/NSM  For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca. Media RelationsKaren Birmingham UK/Global +44 203 749 5634Rob Skelding UK/Global +44 203 749 5821Matt Kent UK/Global +44 203 749 5906Gonzalo Viña UK/Global +44 203 749 5916Jacob Lund Sweden +46 8 553 260 20Michele Meixell US +1 302 885 2677 Investor RelationsThomas Kudsk Larsen +44 203 749 5712Josie Afolabi +44 203 749 5631Craig Marks Finance; Fixed Income; M&A +44 7881 615 764Henry Wheeler Oncology +44 203 749 5797Mitchell Chan Oncology; Other +1 240 477 3771Christer Gruvris Brilinta; Diabetes +44 203 749 5711Nick Stone Respiratory; Renal +44 203 749 5716Jennifer Kretzmann Retail Investors +44 203 749 5824US toll-free +1 866 381 7277 Adrian KempCompany SecretaryAstraZeneca PLC This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END

Study with IQWave™ D-EECT gets Ethical Committee approval

We are very proud to announce that the Ethical Committee at PPUM has approved the suggested study on IQWave™ D-EECT for larger locally advanced tumours. The study may start as soon as Abex Medical System Sdn. Bhd. ('ABEX') receives its first IQWave™-device and the treating doctors have been trained and certified from one of ChemoTechs global Key Opinion Leaders. The study will initially include a small number of patients under the ‘special access program’ that PPUM received approval for earlier this year. Once again ABEX has through its professionalism showed us that they value our partnership deeply and has allocated all the recourses needed to launch IQWave™ in Malaysia, says Mohan Frick, CEO at ChemoTech. PPUM is formerly known as ‘University Hospital’ is a government-funded medical institution located in Pantai Dalam, southwest corner of Kuala Lumpur, the dynamic and bustling capital city of Malaysia. It was established by Statute in September 1962 and is part of University of Malaya. The objectives of PPUM are to establish, operate and develop a medical centre of international standard and repute; and to co-operate with Faculty in providing facilities for medical education, training, research, internship and consultancy. This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU’s market abuse regulation. The information was submitted by the agency of below stated contact person, to be made public on Friday June 22nd 2018 at 10.30 (CET). For more information, please contact: Mohan Frick, CEO +46 (0)10-218 93 00 +65 9014 5008 info@chemotech.se Scandinavian ChemoTech AB (publ) www.chemotech.se ChemoTech is a young and dynamic life science company that possesses a great medical expertise and technical knowledge. Our latest launch of IQWave™ is an innovation within electrochemotherapy, that is adapted for the treatment of different types of tumors. ChemoTech strives to contribute to a more accessible cancer care. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. The company is headquartered in Malmö, in the midst of the medical technology expansionary Öresund region.

Invitation to the presentation of Gjensidige's results for the 2nd quarter 2018

Gjensidige Forsikring Group (OSE:GJF) will publish the results for the 2nd quarter 2018 on 13 July at 7.00 CET. 13 July (Oslo) 9.00 CET CEO Helge Leiro Baastad and CFO Jostein Amdal will present the results in a combined webcast and conference call the same day at 9.00 CET. The presentation and following Q&A session will be held in English. The webcast can be viewed live on www.gjensidige.no/ir. Participants who would like to ask questions should dial in using one of the telephone numbers below. The full presentation can also be listened to live, using the same dial-in details. Dial-in details for the presentation and Q&A session: Confirmation code: 7484536 Norway: +47 800 51084 UK/ Europe: +44 (0) 800 358 6377 USA: +1 800-239-9838 Other locations: Please choose one of the above A replay of the presentation and Q&A session will be made available from 13 July at approximately 12.00 CET. Replay phone number: +47 23 50 00 77 Replay passcode: 7484536 11.00 CET CEO Helge Leiro Baastad and CFO Jostein Amdal will be available for a Q&A session for investors and sell-side analysts at Gjensidige's head office, Schweigaards gate 21 in Oslo. Investors and sell-side analysts who wish to attend the Q&A session in Oslo are requested to register by e-mail to ir@gjensidige.no by end of business 11 July. For more information about Gjensidige, please visit www.gjensidige.no/group. Contact persons, Gjensidige Forsikring ASA: Head of Investor Relations: Mitra Hagen Negård, tel.: +47 957 93 631 Head of Communication: Øystein Thoresen, tel.: +47 952 33 382

Nordic Nanovector Appoints Eduardo Bravo as Chief Executive Officer

Oslo, Norway, 25 June 2018 Nordic Nanovector ASA (OSE: NANO) announces that Eduardo Bravo has been appointed as its Chief Executive Officer. Mr Bravo brings more than 25 years’ experience in the biopharmaceutical industry and a strong track record in leading and growing international biotech and pharmaceutical organisations. Since 2011, as CEO of TiGenix, a dual-listed (Euronext Brussels and NASDAQ) biopharmaceutical company developing novel stem cell therapies, he successfully developed the company through several financing rounds, led its IPO on NASDAQ, and secured European marketing approval of its lead asset. In January 2018, Takeda Pharmaceutical Co. Ltd announced it was acquiring TiGenix for €520 million. Prior to joining TiGenix’ predecessor, Cellerix, in 2005, Mr Bravo held several senior management positions at Sanofi-Aventis and SmithKline Beecham. He is currently Chairman of Vivet Therapeutics. He holds a degree in Business Administration and an MBA (INSEAD). Mr Bravo will take up the CEO position in Nordic Nanovector on 2 July and will be based in London, UK. Ludvik Sandnes, Chairman of Nordic Nanovector’s Board of Directors, said: “I am very pleased that we have attracted someone of Eduardo’s calibre to become the CEO of Nordic Nanovector. He has extensive experience in corporate and product development, which is central to Nordic Nanovector’s future success, and will provide excellent leadership under which the Company can continue to realise its significant potential with Betalutin®. I would also like to thank Tone Kvåle for supporting the company as Interim CEO over the past few months.” Eduardo Bravo added: “I am looking forward to this exciting new role as the CEO of Nordic Nanovector. It is clear that the Company has an exciting future based on the significant potential of Betalutin® in follicular lymphoma and NHL more broadly. I am joining an excellent board and management team and am confident that with my complementary experience and networks, we can succeed with Betalutin® to provide physicians with another treatment option to improve the lives of patients who are in dire need of effective therapies to control their disease and build significant value in the company.” On joining Nordic Nanovector, Mr Bravo will be granted 250,000 PSUs (performance share units) and the company's Board of Directors has undertaken to grant him a further 50,000 PSUs as part of the company's annual grant of PSUs in the first quarter of 2019. For further information about the PSUs and the related warrants, see pages 66-68 in the company's annual report for 2017. In addition, on joining Nordic Nanovector, Mr Bravo will receive a sign-on bonus of EUR 50,000 and has undertaken to invest, at minimum, the net amount after tax in Nordic Nanovector shares and will do so following this announcement. For further information, please contact: Ludvik Sandnes, Chairman Cell: +47 907 43017 Email: lsandnes@nordicnanovector.com International Media Enquiries Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson) Tel: +44 207 638 9571 Email: nordicnanovector@citigatedr.co.uk  About Nordic Nanovector Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com